

**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

Only for new nonprovisional applications under 37 CFR 1.53(b)

10/13/99  
66  
C  
G  
S  
U  
S

10/13/99  
66/47251

Attorney Docket No. BB1085 US NA

First Named Inventor or Application Identifier

REBECCA E. CAHOON ET AL.

Express Mail Label No. EK021890231US

Express Mailing Date OCTOBER 13, 1999

**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

<p>1. <input checked="" type="checkbox"/> Fee (Authority to charge deposit account below.) (Submit an original, and a duplicate for fee processing)</p> <p>2. <input checked="" type="checkbox"/> Specification [Total Pages 30] 1</p> <ul style="list-style-type: none"> <li>- Descriptive title of the invention</li> <li>- Cross References to Related Applications (if needed)</li> <li>- Statement Regarding Fed sponsored R &amp; D (if needed)</li> <li>- Reference to Microfiche Appendix (if filed)</li> <li>- Background of the Invention</li> <li>- Brief Summary of the Invention</li> <li>- Brief Description of the Drawings (if filed)</li> <li>- Detailed Description</li> <li>- Claim(s)</li> <li>- Abstract of the Disclosure</li> </ul> <p>3. <input type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets 0]</p> <p>4. <input checked="" type="checkbox"/> Oath or Declaration [Total Pages 2]</p> <ul style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> Newly executed (original or copy) (unsigned)</li> <li>b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 14 completed)</li> </ul> <p>i. <input type="checkbox"/> <b>DELETION OF INVENTORS</b></p> <ul style="list-style-type: none"> <li>Signed Statement below at 15 deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</li> </ul> <p>5. <input type="checkbox"/> Incorporation by Reference (useable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference thereto.</p>	<p>6. <input type="checkbox"/> Microfiche Computer Program (Appendix)</p> <p>7. <input type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)</p> <ul style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> Computer Readable Copy</li> <li>b. <input checked="" type="checkbox"/> Paper Copy (identical to computer copy)</li> <li>c. <input checked="" type="checkbox"/> Statement verifying identity of above copies</li> </ul>
--	---

**ACCOMPANYING APPLICATION PARTS**

<p>8. <input type="checkbox"/> Power of Attorney</p> <p>9. <input type="checkbox"/> Information Disclosure Statement (IDS)/Cover Letter plus PTO-1449</p>	<p><input type="checkbox"/> Copies of IDS Citations</p>
<p>10. <input type="checkbox"/> Preliminary Amendment</p> <p>11. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)</p> <p>12. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed)</p>	
<p>13. <input checked="" type="checkbox"/> Other: <u>Sequence Listing (19 pages) and Gene Sequence Listing Diskette</u></p>	

14. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

Continuation     Divisional     Continuation-in-part (CIP)    of prior Application No. /

15.  **DELETION OF INVENTOR(S) STATEMENT:** This application is being filed by less than all the inventors named in the prior application. In accordance with 37 CFR 1.63(d)(2) and 1.33(b), the Assistant Commissioner is requested to delete the name(s) of the following person or persons who are not inventors of the invention being claimed in this application:

16.  Amend the specification by inserting before the first line the sentence:  
-- This application claims priority benefit of U.S. Provisional Application No. 60/104,426 filed October 15, 1998, now pending. --

17.  Cancel in this application original claims \_\_\_\_\_ of the prior application before calculating the filing. (At least one original independent claim must be retained for filing purposes.)

18.  Priority of foreign Application No. \_\_\_\_\_ filed on \_\_\_\_\_ in \_\_\_\_\_  
(country) is claimed under 35 U.S.C. 119.

CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	<b>TOTAL CLAIMS</b> (37 CFR 1.16(e))	<b>15 - 20 =</b>	<b>0</b>	<b>x \$ 18 =</b>	<b>0</b>
	<b>INDEPENDENT CLAIMS</b> (37 CFR 1.16(b))	<b>6 - 3 =</b>	<b>3</b>	<b>x \$ 78 =</b>	<b>\$ 234.00</b>
	<b>MULTIPLE DEPENDENT CLAIM(S)</b> (if applicable)			<b>+ \$ 260 =</b>	<b>0</b>
				<b>BASIC FEE (37 CFR 1.16(a))</b>	<b>+ \$ 760.00</b>
				<b>TOTAL =</b>	<b>\$ 994.00</b>

19. The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 04-1928:


- a.  Fees required under 37 CFR 1.16.
- b.  Fees required under 37 CFR 1.17.

20.  Other:

**21. CORRESPONDENCE ADDRESS**

NAME	Gregory J. Feulner			
ADDRESS	E. I. du Pont de Nemours and Company Legal - Patents 1007 Market Street			
CITY	Wilmington	STATE	Delaware	ZIP CODE
COUNTRY	U.S.A.	TELEPHONE	302-992-3749	FAX
				19898 302-892-7949

**22. SIGNATURE OF ATTORNEY OR AGENT REQUIRED**

NAME	Gregory J. Feulner	REG. NO.: 41,744
SIGNATURE		
DATE	October 16, 1999	

TITLE

## PLANT PROTEIN DISULFIDE ISOMERASES

This application claims the benefit of U.S. Provisional Application No. 60/049,408, filed October 15, 1998.

5

## FIELD OF THE INVENTION

This invention is in the field of plant molecular biology. More specifically, this invention pertains to nucleic acid fragments encoding protein disulfide isomerases in plants and seeds.

## BACKGROUND OF THE INVENTION

10

Protein folding requires the assistance of folding helpers *in vivo*. The formation or isomerization of disulfide bonds in proteins is a slow process requiring catalysis. In nascent polypeptide chains the cysteine residues are in the thiol form. The formation of the disulfide bonds usually occurs simultaneously with the folding of the polypeptide, in the endoplasmic reticulum of eukaryotes or in the periplasm of Gram-negative bacteria. Cells contain three 15 types of accessory proteins that function to assist polypeptides in folding to their native conformations: protein disulfide isomerases, propyl cis-trans isomerases, and molecular chaperones.

20

Protein disulfide isomerase (PDI) is a homodimeric eukaryotic enzyme which catalyzes disulfide interchange reactions. PDI is also thought to be the beta subunit of the heterotetramer prolyl hydrolase, the enzyme that hydroxylates the proline residues in Collagen. PDI appears to belong to a family of closely related proteins which have specific functions. PDI (EC 5.3.4.1), also called S-S rearrangase, catalyzes the rearrangement of both intrachain and interchain disulfide bonds in proteins to form native structures. The reaction depends on sulfhydryl-disulfide interchange, and PDI needs reducing agents or partly-reduced enzyme. A family of PDI-like proteins has been identified in mammals, yeasts, fungi, plants, and *Drosophila*.

25

In *Drosophila*, a PDI precursor was identified by screening a genomic DNA library at reduced stringency hybridization conditions using a rat Phospholipase C alpha cDNA probe. Northern analysis showed that this gene encodes a transcript that is present throughout development, in heads and bodies of adults. The encoded protein contains two domains exhibiting high similarity to thioredoxin, two regions that are similar to the hormone binding domain of human estrogen receptor, and a C-terminal ER-retention signal (KDEL). Overall, this *Drosophila* PDI gene contains a higher similarity to rat protein disulfide isomerase (53% identical) than to rat Phospholipase C alpha (30% identical) 30 (McKay et al. (1995) *Insect Biochem. Mol. Biol.* 25:647-654).

35

Another member of the PDI family is ERp60, a PDI isoform initially misidentified as a phosphatidylinositol-specific phospholipase C. The human and *Drosophila* ERp60 polypeptides have been cloned and expressed. These two ERp60 polypeptides are similar to

human PDI within almost all their domains, the only exception being the extreme C-terminal region. Coexpression in insect cells of the human or Drosophila ERp60 with the alpha subunit of human propyl 4-hydrolase does not result in tetramer formation or prolyl 4-hydroxylase activity in the cells. This lack of tetramer formation is not only due to the differences in the C-terminal region since no prolyl 4-hydroxylase tetramer is formed when a human ERp60 hybrid containing the C-terminal region of the human PDI polypeptide is used (Koivunen et al. (1996) *Biochem. J.* 316:599-605). The 5' flanking region of the ERp60 gene has no TATAA box or CCAAT motif but contains several potential binding sites for transcription factors. The highest levels of expression of the human ERp60 mRNA are found in the liver, placenta, lung, pancreas, and kidney, and the lowest in the heart, skeletal muscle, and brain. The ERp60 gene has been mapped by fluorescence *in situ* hybridization to 15q15, a different chromosome than where the human PDI and thioredoxin genes are found (Koivunen et al. (1997) *Genomics* 42:397-404).

Full-length cDNA clones encoding two members of the mice PDI family have been cloned, sequenced, and expressed (ERp59/PDI and ERp72). ERp59/PDI has been identified as the microsomal PDI. The ERp72 amino acid sequence shares sequence identity with ERp59/PDI at three discrete regions, having three copies of the sequences that are thought to be the CGHC-containing active sites of ERp59/PDI. ERp59/PDI has the sequence Lys-Asp-Glu-Leu at its COOH terminus while ERp72 has the related sequence Lys-Glu-Glu-Leu (Mazzarella et al. (1990) *J. Biol. Chem.* 265:1094-1101). A cDNA clone containing sequence similarity to the mammalian luminal endoplasmic reticulum protein ERp72 has been isolated from an alfalfa (*Medicago sativa* L.) cDNA library by screening with a cDNA encoding human PDI. The polypeptide encoded by this cDNA possesses a putative N-terminal secretory signal sequence and two regions identical to the active sites of PDI and ERp72. This protein appears to be encoded by a small gene family in alfalfa, whose transcripts are constitutively expressed in all major organs of the plant. In alfalfa cell suspension cultures, ERp72 transcripts are induced by treatment with tunicamycin, but not in response to calcium ionophore, heat shock or fungal elicitor (Shorrosh and Dixon (1992) *Plant J.* 2:51-58).

Another member of the PDI family is ERp5. The amino acid sequence deduced from this cDNA insert contains two copies of the 11-amino-acid sequence Val-Glu-Phe-Tyr-Ala-Pro-Trp-Cys-Gly-His-Cys. Duplicate copies of this sequence are found in the active sites of rat and human PDI and in Form I phosphoinositide-specific phospholipase C. Genomic sequences similar to the cDNA clone are amplified 10-20-fold in hamster cells selected for resistance to increasing concentrations of hydroxyurea, a phenomenon observed earlier with cDNA clones for the M2 subunit of ribonucleotide reductase and ornithine decarboxylase. RNA blots probed with ERp5 cDNA show two poly(A)+ RNA species which are elevated in hydroxyurea-resistant cells (Chaudhuri et. al. (1992) *Biochem. J.* 281:645-650).

5 A PDI-like protein from *Acanthamoeba castellanii* contains two highly conserved thioredoxin-like domains, each about 100 amino acids. However, the *A. castellanii* PDI-like protein differs from other members in many aspects, including the overall organization and isoelectric point. Southern and Northern analyses demonstrate that the PDI-like protein is encoded by a single-copy gene which is transcribed to generate a 1500-nucleotide mRNA (Wong and Bateman (1994) *Gene* 150:175-179).

10 The *Chlamydomonas* RB60 gene encodes a chloroplast-localized PDI which is involved in the redox-regulated binding of chloroplast poly(A)-binding protein to the 5'-leader region of psbA mRNA. Protein disulfide isomerase RB60 regulates chloroplast translational activation (Kim and Mayfield (1997) *Science* 278:1954-1957).

15 High level gene expression does not always lead to corresponding high level secretion of heterologous proteins. The rate limiting step has been shown, in many cases, to be the processing and exit of the protein from the endoplasmic reticulum. Proteins or peptides with high levels of disulfide bonds can be adversely affected during expression.

20 Therefore, coexpression and/or overexpression of PDIs could significantly enhance expression levels of many heterologous proteins. An example would be the coexpression of PDIs with insect-selective neurotoxins, since many of these are highly enriched in cysteines and feature multiple disulfide bonds.

25 Protein disulfide isomerases have been described in alfalfa (2 genes and one probable

30 PDI P5 homolog), barley (2 genes, and one probable PDI P5 homolog), maize, wheat, tobacco, and castor bean. In addition, based on sequence similarity to other known PDIs, two putative protein disulfide isomerases have been identified in *Arabidopsis*. Included in this application are corn, and soybean ESTs with sequence similarities to protein disulfide isomerase precursor. The corn sequences included share no similarity with the known maize PDI. Also included are corn, balsam pear, soybean, and the wheat ESTs with sequence similarities to RB60. Presently there are no plant RB60-homologs in the public domain. Overexpression of any of these PDIs together with another foreign protein will result in an increased yield of secreted, active foreign protein due to proper folding of the foreign protein.

35 Present in the NCBI database are corn and soybean sequences with similarities to the polynucleotides included in the present application. These ESTs have NCBI General Identifier NOs:4289796, 4827500, 5124153, 5325044, 5361231, 5525515, 5597319, 5650368, 5688597, 5714111, 5770161, and 5804735.

#### SUMMARY OF THE INVENTION

40 The present invention relates to isolated polynucleotides comprising a nucleotide sequence encoding a protein disulfide isomerase precursor polypeptide of at least 100 amino acids that has at least 85% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of a corn protein disulfide

isomerase precursor polypeptide selected from the group consisting of SEQ ID NO:2, and SEQ ID NO:6, a soybean protein disulfide isomerase precursor polypeptide of SEQ ID NO:4. The present invention relates to isolated polynucleotides comprising a nucleotide sequence encoding an RB60 polypeptide of at least 100 amino acids that has at least 85% 5 identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of a balsam pear RB60 polypeptide of SEQ ID NO:8, a corn RB60 polypeptide selected from the group consisting of SEQ ID NO:10 and SEQ ID NO:12, a soybean RB60 polypeptide selected from the group consisting of SEQ ID NO:14 and SEQ 10 ID NO:16, and a wheat RB60 polypeptide selected from the group consisting of SEQ ID NO:18 and SEQ ID NO:20. The present invention also relates to an isolated polynucleotide comprising the complement of the nucleotide sequences described above.

It is preferred that the isolated polynucleotides of the claimed invention consist of a nucleic acid sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, and 19 that codes for the polypeptide selected from the group consisting of SEQ 15 ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18 and 20. The present invention also relates to an isolated polynucleotide comprising a nucleotide sequences of at least one of 40 (preferably at least one of 30, most preferably at least one of 15) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, and 19 and the complement of such nucleotide sequences.

20 The present invention relates to a chimeric gene comprising an isolated polynucleotide of the present invention operably linked to suitable regulatory sequences.

The present invention relates to an isolated host cell comprising a chimeric gene of the present invention or an isolated polynucleotide of the present invention. The host cell may be eukaryotic, such as a yeast or a plant cell, or prokaryotic, such as a bacterial cell or virus. 25 A virus host cell of the present invention is preferably a baculovirus. The baculovirus preferably comprises an isolated polynucleotide of the present invention or a chimeric gene of the present invention.

The present invention relates to a process for producing an isolated host cell comprising a chimeric gene of the present invention or an isolated polynucleotide of the 30 present invention, the process comprising either transforming or transfecting an isolated compatible host cell with a chimeric gene or isolated polynucleotide of the present invention.

The present invention relates to a protein disulfide isomerase precursor or an RB60 polypeptide of at least 100 amino acids comprising at least 85% homology based on the Clustal method of alignment compared to a polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, and 20.

35 The present invention relates to a method of selecting an isolated polynucleotide that affects the level of expression of a protein disulfide isomerase precursor or an RB60 polypeptide in a host cell, the method comprising the steps of:

constructing an isolated polynucleotide of the present invention or an isolated chimeric gene of the present invention;

introducing the isolated polynucleotide or the isolated chimeric gene into a host cell (preferably a plant cell);

5 measuring the level a protein disulfide isomerase precursor or an RB60 polypeptide in the plant cell containing the isolated polynucleotide; and

comparing the level of a protein disulfide isomerase precursor or an RB60 polypeptide in the host cell containing the isolated polynucleotide with the level of a protein disulfide isomerase precursor or an RB60 polypeptide in a host cell that does not contain the 10 isolated polynucleotide.

The present invention relates to a method of obtaining a nucleic acid fragment encoding a substantial portion of a protein disulfide isomerase precursor or an RB60 polypeptide gene, preferably a plant protein disulfide isomerase precursor or an RB60 polypeptide gene, comprising the steps of: synthesizing an oligonucleotide primer

15 comprising a nucleotide sequence of at least one of 40 (preferably at least one of 30, most preferably at least one of 15) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, and 19 and the complement of such nucleotide sequences; and amplifying a nucleic acid fragment (preferably a cDNA inserted in a cloning vector) using the oligonucleotide primer. The 20 amplified nucleic acid fragment preferably will encode a portion of a protein disulfide isomerase precursor or an RB60 amino acid sequence.

The present invention also relates to a method of obtaining a nucleic acid fragment encoding all or a substantial portion of the amino acid sequence encoding a protein disulfide isomerase precursor or an RB60 polypeptide comprising the steps of: probing a cDNA or genomic library with an isolated polynucleotide of the present invention; identifying a DNA clone that hybridizes with an isolated polynucleotide of the present invention; isolating the identified DNA clone; and sequencing the cDNA or genomic fragment that comprises the isolated DNA clone.

#### **BRIEF DESCRIPTION OF THE SEQUENCE LISTING**

30 The invention can be more fully understood from the following detailed description and the accompanying Sequence Listing which form a part of this application.

Table 1 lists the polypeptides that are described herein, the designation of the cDNA clones that comprise the nucleic acid fragments encoding polypeptides representing all or a substantial portion of these polypeptides, and the corresponding identifier (SEQ ID NO:) as 35 used in the attached Sequence Listing. The sequence descriptions and Sequence Listing attached hereto comply with the rules governing nucleotide and/or amino acid sequence disclosures in patent applications as set forth in 37 C.F.R. §1.821-1.825.

**TABLE 1**  
**Protein Disulfide Isomerases**

Protein	Clone Designation	(Nucleotide)	SEQ ID NO: (Amino Acid)
Corn PDI precursor	cr1n.pk0090.d2	1	2
Soybean PDI precursor	srt3c.pk002.a8	3	4
Corn PDI precursor	cs1.pk0032.c9	5	6
Balsam Pear RB60	fds.pk0022.c11	7	8
Corn PDI RB60	Contig of: cen3n.pk0155.e7 cs1.pk0100.a7 p0032.crcbb52r p0125.czabp07r	9	10
Corn PDI RB60	cs1.pk0077.f10	11	12
Soybean PDI RB60	sr1.pk0095.e9	13	14
Soybean PDI RB60	Contig of: scr1c.pk005.i17 sdp2c.pk038.e22 sdp3c.pk021.a3 sfl1.pk0026.h1 sl2.pk0075.b10	15	16
Wheat PDI RB60	wl1n.pk0027.f4	17	18
Wheat PDI RB60	wre1n.pk0015.d10	19	20

5 The Sequence Listing contains the one letter code for nucleotide sequence characters and the three letter codes for amino acids as defined in conformity with the IUPAC-IUBMB standards described in *Nucleic Acids Res.* 13:3021-3030 (1985) and in the *Biochemical J.* 219 (No. 2):345-373 (1984) which are herein incorporated by reference. The symbols and format used for nucleotide and amino acid sequence data comply with the rules set forth in 37 C.F.R. §1.822.

10 **DETAILED DESCRIPTION OF THE INVENTION**

In the context of this disclosure, a number of terms shall be utilized. As used herein, a "polynucleotide" is a nucleotide sequence such as a nucleic acid fragment. A polynucleotide may be a polymer of RNA or DNA that is single- or double-stranded, that optionally contains synthetic, non-natural or altered nucleotide bases. A polynucleotide in the form of 15 a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA, or synthetic DNA. An isolated polynucleotide of the present invention may include at least one of 40 contiguous nucleotides, preferably at least one of 30 contiguous nucleotides, most preferably one of at least 15 contiguous nucleotides, of the nucleic acid sequence of the SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, or 19.

As used herein, "contig" refers to a nucleotide sequence that is assembled from two or more constituent nucleotide sequences that share common or overlapping regions of sequence homology. For example, the nucleotide sequences of two or more nucleic acid fragments can be compared and aligned in order to identify common or overlapping

5 sequences. Where common or overlapping sequences exist between two or more nucleic acid fragments, the sequences (and thus their corresponding nucleic acid fragments) can be assembled into a single contiguous nucleotide sequence.

As used herein, "substantially similar" refers to nucleic acid fragments wherein changes in one or more nucleotide bases results in substitution of one or more amino acids, 10 but do not affect the functional properties of the polypeptide encoded by the nucleotide sequence. "Substantially similar" also refers to nucleic acid fragments wherein changes in one or more nucleotide bases does not affect the ability of the nucleic acid fragment to mediate alteration of gene expression by gene silencing through for example antisense or co-suppression technology. "Substantially similar" also refers to modifications of the nucleic

15 acid fragments of the instant invention such as deletion or insertion of one or more nucleotides that do not substantially affect the functional properties of the resulting transcript vis-a-vis the ability to mediate gene silencing or alteration of the functional properties of the resulting protein molecule. It is therefore understood that the invention encompasses more than the specific exemplary nucleotide or amino acid sequences and 20 includes functional equivalents thereof.

Substantially similar nucleic acid fragments may be selected by screening nucleic acid fragments representing subfragments or modifications of the nucleic acid fragments of the instant invention, wherein one or more nucleotides are substituted, deleted and/or inserted, for their ability to affect the level of the polypeptide encoded by the unmodified nucleic acid 25 fragment in a plant or plant cell. For example, a substantially similar nucleic acid fragment representing at least one of 30 contiguous nucleotides derived from the instant nucleic acid fragment can be constructed and introduced into a plant or plant cell. The level of the polypeptide encoded by the unmodified nucleic acid fragment present in a plant or plant cell exposed to the substantially similar nucleic fragment can then be compared to the level of 30 the polypeptide in a plant or plant cell that is not exposed to the substantially similar nucleic acid fragment.

For example, it is well known in the art that antisense suppression and co-suppression of gene expression may be accomplished using nucleic acid fragments representing less than the entire coding region of a gene, and by nucleic acid fragments that 35 do not share 100% sequence identity with the gene to be suppressed. Moreover, alterations in a nucleic acid fragment which result in the production of a chemically equivalent amino acid at a given site, but do not effect the functional properties of the encoded polypeptide, are well known in the art. Thus, a codon for the amino acid alanine, a hydrophobic amino

acid, may be substituted by a codon encoding another less hydrophobic residue, such as glycine, or a more hydrophobic residue, such as valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine 5 for arginine, can also be expected to produce a functionally equivalent product. Nucleotide changes which result in alteration of the N-terminal and C-terminal portions of the polypeptide molecule would also not be expected to alter the activity of the polypeptide. Each of the proposed modifications is well within the routine skill in the art, as is 10 determination of retention of biological activity of the encoded products. Consequently, an 10 isolated polynucleotide comprising a nucleotide sequence of at least one of 40 (preferably at least one of 30, most preferably at least one of 15) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19 and the complement of such nucleotide sequences may be used in methods of 15 selecting an isolated polynucleotide that affects the expression of a polypeptide (such as PDI precursor or PDI RB60) in a host cell. A method of selecting an isolated polynucleotide that affects the level of expression of a polypeptide in a host cell (eukaryotic, such as plant, or prokaryotic such as yeast bacterial or virus) may comprise the steps of: constructing an 20 isolated polynucleotide of the present invention or an isolated chimeric gene of the present invention; introducing the isolated polynucleotide or the isolated chimeric gene into a host cell; measuring the level a polypeptide in the host cell containing the isolated polynucleotide; and comparing the level of a polypeptide in the host cell containing the isolated polynucleotide with the level of a polypeptide in a host cell that does not contain the isolated polynucleotide.

Moreover, substantially similar nucleic acid fragments may also be characterized by 25 their ability to hybridize. Estimates of such homology are provided by either DNA-DNA or DNA-RNA hybridization under conditions of stringency as is well understood by those skilled in the art (Hames and Higgins, Eds. (1985) Nucleic Acid Hybridisation, IRL Press, Oxford, U.K.). Stringency conditions can be adjusted to screen for moderately similar fragments, such as homologous sequences from distantly related organisms, to highly similar 30 fragments, such as genes that duplicate functional enzymes from closely related organisms. Post-hybridization washes determine stringency conditions. One set of preferred conditions uses a series of washes starting with 6X SSC, 0.5% SDS at room temperature for 15 min, then repeated with 2X SSC, 0.5% SDS at 45°C for 30 min, and then repeated twice with 0.2X SSC, 0.5% SDS at 50°C for 30 min. A more preferred set of stringent conditions uses 35 higher temperatures in which the washes are identical to those above except for the temperature of the final two 30 min washes in 0.2X SSC, 0.5% SDS was increased to 60°C. Another preferred set of highly stringent conditions uses two final washes in 0.1X SSC, 0.1% SDS at 65°C.

Substantially similar nucleic acid fragments of the instant invention may also be characterized by the percent identity of the amino acid sequences that they encode to the amino acid sequences disclosed herein, as determined by algorithms commonly employed by those skilled in this art. Suitable nucleic acid fragments (isolated polynucleotides of the

5 present invention) encode polypeptides that are 80% identical to the amino acid sequences reported herein. Preferred nucleic acid fragments encode amino acid sequences that are 85% identical to the amino acid sequences reported herein. More preferred nucleic acid fragments encode amino acid sequences that are 90% identical to the amino acid sequences reported herein. Most preferred are nucleic acid fragments that encode amino acid

10 sequences that are 95% identical to the amino acid sequences reported herein. Suitable nucleic acid fragments not only have the above identities but typically encode a polypeptide having at least 50 amino acids, preferably 100 amino acids, more preferably 150 amino acids, still more preferably 200 amino acids, and most preferably 250 amino acids.

Sequence alignments and percent identity calculations were performed using the Megalign 15 program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS* 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise 20 alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5.

A "substantial portion" of an amino acid or nucleotide sequence comprises an amino acid or a nucleotide sequence that is sufficient to afford putative identification of the protein or gene that the amino acid or nucleotide sequence comprises. Amino acid and nucleotide sequences can be evaluated either manually by one skilled in the art, or by using computer-based sequence comparison and identification tools that employ algorithms such as BLAST 25 (Basic Local Alignment Search Tool; Altschul et al. (1993) *J. Mol. Biol.* 215:403-410; see also [www.ncbi.nlm.nih.gov/BLAST/](http://www.ncbi.nlm.nih.gov/BLAST/)). In general, a sequence of ten or more contiguous amino acids or thirty or more contiguous nucleotides is necessary in order to putatively identify a polypeptide or nucleic acid sequence as homologous to a known protein or gene.

30 Moreover, with respect to nucleotide sequences, gene-specific oligonucleotide probes comprising 30 or more contiguous nucleotides may be used in sequence-dependent methods of gene identification (e.g., Southern hybridization) and isolation (e.g., *in situ* hybridization of bacterial colonies or bacteriophage plaques). In addition, short oligonucleotides of 12 or more nucleotides may be used as amplification primers in PCR in order to obtain a particular 35 nucleic acid fragment comprising the primers. Accordingly, a "substantial portion" of a nucleotide sequence comprises a nucleotide sequence that will afford specific identification and/or isolation of a nucleic acid fragment comprising the sequence. The instant specification teaches amino acid and nucleotide sequences encoding polypeptides that

comprise one or more particular plant proteins. The skilled artisan, having the benefit of the sequences as reported herein, may now use all or a substantial portion of the disclosed sequences for purposes known to those skilled in this art. Accordingly, the instant invention comprises the complete sequences as reported in the accompanying Sequence Listing, as well as substantial portions of those sequences as defined above.

5 "Codon degeneracy" refers to divergence in the genetic code permitting variation of the nucleotide sequence without effecting the amino acid sequence of an encoded polypeptide. Accordingly, the instant invention relates to any nucleic acid fragment comprising a nucleotide sequence that encodes all or a substantial portion of the amino acid sequences set forth herein. The skilled artisan is well aware of the "codon-bias" exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid.

10 Therefore, when synthesizing a nucleic acid fragment for improved expression in a host cell, it is desirable to design the nucleic acid fragment such that its frequency of codon usage approaches the frequency of preferred codon usage of the host cell.

15 "Synthetic nucleic acid fragments" can be assembled from oligonucleotide building blocks that are chemically synthesized using procedures known to those skilled in the art. These building blocks are ligated and annealed to form larger nucleic acid fragments which may then be enzymatically assembled to construct the entire desired nucleic acid fragment. "Chemically synthesized", as related to nucleic acid fragment, means that the component nucleotides were assembled *in vitro*. Manual chemical synthesis of nucleic acid fragments may be accomplished using well established procedures, or automated chemical synthesis can be performed using one of a number of commercially available machines. Accordingly, the nucleic acid fragments can be tailored for optimal gene expression based on optimization of nucleotide sequence to reflect the codon bias of the host cell. The skilled artisan

20 appreciates the likelihood of successful gene expression if codon usage is biased towards those codons favored by the host. Determination of preferred codons can be based on a survey of genes derived from the host cell where sequence information is available.

25 "Gene" refers to a nucleic acid fragment that expresses a specific protein, including regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence. "Native gene" refers to a gene as found in nature with its own regulatory sequences. "Chimeric gene" refers any gene that is not a native gene, comprising regulatory and coding sequences that are not found together in nature. Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived

30 from the same source, but arranged in a manner different than that found in nature. "Endogenous gene" refers to a native gene in its natural location in the genome of an organism. A "foreign" gene refers to a gene not normally found in the host organism, but that is introduced into the host organism by gene transfer. Foreign genes can comprise

native genes inserted into a non-native organism, or chimeric genes. A “transgene” is a gene that has been introduced into the genome by a transformation procedure.

“Coding sequence” refers to a nucleotide sequence that codes for a specific amino acid sequence. “Regulatory sequences” refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, and polyadenylation recognition sequences.

“Promoter” refers to a nucleotide sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' to a promoter sequence. The promoter sequence consists of proximal and more distal upstream elements, the latter elements often referred to as enhancers. Accordingly, an “enhancer” is a nucleotide sequence which can stimulate promoter activity and may be an innate element of the promoter or a heterologous element inserted to enhance the level or tissue-specificity of

15 a promoter. Promoters may be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise synthetic nucleotide segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental conditions.

20 Promoters which cause a nucleic acid fragment to be expressed in most cell types at most times are commonly referred to as “constitutive promoters”. New promoters of various types useful in plant cells are constantly being discovered; numerous examples may be found in the compilation by Okamuro and Goldberg (1989) *Biochemistry of Plants* 15:1-82. It is further recognized that since in most cases the exact boundaries of regulatory sequences 25 have not been completely defined, nucleic acid fragments of different lengths may have identical promoter activity.

The “translation leader sequence” refers to a nucleotide sequence located between the promoter sequence of a gene and the coding sequence. The translation leader sequence is present in the fully processed mRNA upstream of the translation start sequence. The 30 translation leader sequence may affect processing of the primary transcript to mRNA, mRNA stability or translation efficiency. Examples of translation leader sequences have been described (Turner and Foster (1995) *Mol. Biotechnol.* 3:225-236).

The “3' non-coding sequences” refer to nucleotide sequences located downstream of a coding sequence and include polyadenylation recognition sequences and other sequences 35 encoding regulatory signals capable of affecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor. The use of different 3' non-coding sequences is exemplified by Ingelbrecht et al. (1989) *Plant Cell* 1:671-680.

“RNA transcript” refers to the product resulting from RNA polymerase-catalyzed transcription of a DNA sequence. When the RNA transcript is a perfect complementary copy of the DNA sequence, it is referred to as the primary transcript or it may be a RNA sequence derived from posttranscriptional processing of the primary transcript and is

5 referred to as the mature RNA. “Messenger RNA (mRNA)” refers to the RNA that is without introns and that can be translated into polypeptide by the cell. “cDNA” refers to a double-stranded DNA that is complementary to and derived from mRNA. “Sense” RNA refers to an RNA transcript that includes the mRNA and so can be translated into a polypeptide by the cell. “Antisense RNA” refers to an RNA transcript that is

10 complementary to all or part of a target primary transcript or mRNA and that blocks the expression of a target gene (see U.S. Patent No. 5,107,065, incorporated herein by reference). The complementarity of an antisense RNA may be with any part of the specific nucleotide sequence, i.e., at the 5' non-coding sequence, 3' non-coding sequence, introns, or the coding sequence. “Functional RNA” refers to sense RNA, antisense RNA, ribozyme

15 RNA, or other RNA that may not be translated but yet has an effect on cellular processes.

The term “operably linked” refers to the association of two or more nucleic acid fragments on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., that the coding sequence is under 20 the transcriptional control of the promoter). Coding sequences can be operably linked to regulatory sequences in sense or antisense orientation.

The term “expression”, as used herein, refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from the nucleic acid fragment of the invention. Expression may also refer to translation of mRNA into a polypeptide.

25 “Antisense inhibition” refers to the production of antisense RNA transcripts capable of suppressing the expression of the target protein. “Overexpression” refers to the production of a gene product in transgenic organisms that exceeds levels of production in normal or non-transformed organisms. “Co-suppression” refers to the production of sense RNA transcripts capable of suppressing the expression of identical or substantially similar foreign

30 or endogenous genes (U.S. Patent No. 5,231,020, incorporated herein by reference).

“Altered levels” refers to the production of gene product(s) in transgenic organisms in amounts or proportions that differ from that of normal or non-transformed organisms.

“Mature” protein refers to a post-translationally processed polypeptide; i.e., one from which any pre- or propeptides present in the primary translation product have been removed.

35 “Precursor” protein refers to the primary product of translation of mRNA; i.e., with pre- and propeptides still present. Pre- and propeptides may be but are not limited to intracellular localization signals.

A “chloroplast transit peptide” is an amino acid sequence which is translated in conjunction with a protein and directs the protein to the chloroplast or other plastid types present in the cell in which the protein is made. “Chloroplast transit sequence” refers to a nucleotide sequence that encodes a chloroplast transit peptide. A “signal peptide” is an amino acid sequence which is translated in conjunction with a protein and directs the protein to the secretory system (Chrispeels (1991) *Ann. Rev. Plant Phys. Plant Mol. Biol.* 42:21-53). If the protein is to be directed to a vacuole, a vacuolar targeting signal (*supra*) can further be added, or if to the endoplasmic reticulum, an endoplasmic reticulum retention signal (*supra*) may be added. If the protein is to be directed to the nucleus, any signal peptide present should be removed and instead a nuclear localization signal included (Raikhel (1992) *Plant Phys.* 100:1627-1632).

“Transformation” refers to the transfer of a nucleic acid fragment into the genome of a host organism, resulting in genetically stable inheritance. Host organisms containing the transformed nucleic acid fragments are referred to as “transgenic” organisms. Examples of methods of plant transformation include *Agrobacterium*-mediated transformation (De Blaere et al. (1987) *Meth. Enzymol.* 143:277) and particle-accelerated or “gene gun” transformation technology (Klein et al. (1987) *Nature (London)* 327:70-73; U.S. Patent No. 4,945,050, incorporated herein by reference).

Standard recombinant DNA and molecular cloning techniques used herein are well known in the art and are described more fully in Sambrook et al. *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989 (hereinafter “Maniatis”).

Nucleic acid fragments encoding at least a portion of several PDIs have been isolated and identified by comparison of random plant cDNA sequences to public databases containing nucleotide and protein sequences using the BLAST algorithms well known to those skilled in the art. The nucleic acid fragments of the instant invention may be used to isolate cDNAs and genes encoding homologous proteins from the same or other plant species. Isolation of homologous genes using sequence-dependent protocols is well known in the art. Examples of sequence-dependent protocols include, but are not limited to, methods of nucleic acid hybridization, and methods of DNA and RNA amplification as exemplified by various uses of nucleic acid amplification technologies (e.g., polymerase chain reaction, ligase chain reaction).

For example, genes encoding other PDIs, either as cDNAs or genomic DNAs, could be isolated directly by using all or a portion of the instant nucleic acid fragments as DNA hybridization probes to screen libraries from any desired plant employing methodology well known to those skilled in the art. Specific oligonucleotide probes based upon the instant nucleic acid sequences can be designed and synthesized by methods known in the art (Maniatis). Moreover, the entire sequences can be used directly to synthesize DNA probes

by methods known to the skilled artisan such as random primer DNA labeling, nick translation, or end-labeling techniques, or RNA probes using available *in vitro* transcription systems. In addition, specific primers can be designed and used to amplify a part or all of the instant sequences. The resulting amplification products can be labeled directly during 5 amplification reactions or labeled after amplification reactions, and used as probes to isolate full length cDNA or genomic fragments under conditions of appropriate stringency.

In addition, two short segments of the instant nucleic acid fragments may be used in polymerase chain reaction protocols to amplify longer nucleic acid fragments encoding homologous genes from DNA or RNA. The polymerase chain reaction may also be 10 performed on a library of cloned nucleic acid fragments wherein the sequence of one primer is derived from the instant nucleic acid fragments, and the sequence of the other primer takes advantage of the presence of the polyadenylic acid tracts to the 3' end of the mRNA precursor encoding plant genes. Alternatively, the second primer sequence may be based upon sequences derived from the cloning vector. For example, the skilled artisan can follow

15 the RACE protocol (Frohman et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:8998-9002) to generate cDNAs by using PCR to amplify copies of the region between a single point in the transcript and the 3' or 5' end. Primers oriented in the 3' and 5' directions can be designed from the instant sequences. Using commercially available 3' RACE or 5' RACE systems (BRL), specific 3' or 5' cDNA fragments can be isolated (Ohara et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:5673-5677; Loh et al. (1989) *Science* 243:217-220). Products generated 20 by the 3' and 5' RACE procedures can be combined to generate full-length cDNAs (Frohman and Martin (1989) *Techniques* 1:165). Consequently, a polynucleotide comprising a nucleotide sequence of at least one of 40 (preferably one of at least 30, most preferably one of at least 15) contiguous nucleotides derived from a nucleotide sequence selected from the 25 group consisting of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19 and the complement of such nucleotide sequences may be used in such methods to obtain a nucleic acid fragment encoding a substantial portion of an amino acid sequence of a polypeptide (such as PDI precursor or PDI RB 60). The present invention relates to a method of obtaining a nucleic acid fragment encoding a substantial portion of a polypeptide of a gene (such as PDI 30 precursor or PDI RB 60) preferably a substantial portion of a polypeptide of a plant gene, comprising the steps of: synthesizing an oligonucleotide primer comprising a nucleotide sequence of at least one of 40 (preferably at least one of 30, most preferably at least one of 15) contiguous nucleotides derived from a nucleotide sequence selected from the group 35 consisting of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19 and the complement of such nucleotide sequences; and amplifying a nucleic acid fragment (preferably a cDNA inserted in a cloning vector) using the oligonucleotide primer. The amplified nucleic acid fragment preferably will encode a portion of a polypeptide (such as PDI precursor or PDI RB 60).

Availability of the instant nucleotide and deduced amino acid sequences facilitates immunological screening of cDNA expression libraries. Synthetic peptides representing portions of the instant amino acid sequences may be synthesized. These peptides can be used to immunize animals to produce polyclonal or monoclonal antibodies with specificity 5 for peptides or proteins comprising the amino acid sequences. These antibodies can be then be used to screen cDNA expression libraries to isolate full-length cDNA clones of interest (Lerner (1984) *Adv. Immunol.* 36:1-34; Maniatis).

The nucleic acid fragments of the instant invention may be used to create transgenic plants in which the disclosed polypeptides are present at higher levels than normal or in cell 10 types or developmental stages in which they are not normally found. This would have the effect of altering the level of properly folded proteins in those cells. Coexpression of a member of the PDI family with another foreign protein will result in a greater yield of active, secreted foreign protein due to the improvement in proper folding done by the PDI.

Overexpression of the proteins of the instant invention may be accomplished by first 15 constructing a chimeric gene in which the coding region is operably linked to a promoter capable of directing expression of a gene in the desired tissues at the desired stage of development. For reasons of convenience, the chimeric gene may comprise promoter sequences and translation leader sequences derived from the same genes. 3' Non-coding sequences encoding transcription termination signals may also be provided. The instant 20 chimeric gene may also comprise one or more introns in order to facilitate gene expression.

Plasmid vectors comprising the instant chimeric gene can then be constructed. The choice of plasmid vector is dependent upon the method that will be used to transform host plants. The skilled artisan is well aware of the genetic elements that must be present on the plasmid vector in order to successfully transform, select and propagate host cells containing 25 the chimeric gene. The skilled artisan will also recognize that different independent transformation events will result in different levels and patterns of expression (Jones et al. (1985) *EMBO J.* 4:2411-2418; De Almeida et al. (1989) *Mol. Gen. Genetics* 218:78-86), and thus that multiple events must be screened in order to obtain lines displaying the desired expression level and pattern. Such screening may be accomplished by Southern analysis of 30 DNA, Northern analysis of mRNA expression, Western analysis of protein expression, or phenotypic analysis.

For some applications it may be useful to direct the instant polypeptides to different cellular compartments, or to facilitate its secretion from the cell. It is thus envisioned that the chimeric gene described above may be further supplemented by altering the coding 35 sequence to encode the instant polypeptides with appropriate intracellular targeting sequences such as transit sequences (Keegstra (1989) *Cell* 56:247-253), signal sequences or sequences encoding endoplasmic reticulum localization (Chrispeels (1991) *Ann. Rev. Plant Phys. Plant Mol. Biol.* 42:21-53), or nuclear localization signals (Raikhel (1992) *Plant*

*Phys. 100:1627-1632*) added and/or with targeting sequences that are already present removed. While the references cited give examples of each of these, the list is not exhaustive and more targeting signals of utility may be discovered in the future.

The instant polypeptides (or portions thereof) may be produced in heterologous host cells, particularly in the cells of microbial hosts, and can be used to prepare antibodies to the these proteins by methods well known to those skilled in the art. The antibodies are useful for detecting the polypeptides of the instant invention *in situ* in cells or *in vitro* in cell extracts. Preferred heterologous host cells for production of the instant polypeptides are microbial hosts. Microbial expression systems and expression vectors containing regulatory sequences that direct high level expression of foreign proteins are well known to those skilled in the art. Any of these could be used to construct a chimeric gene for production of the instant polypeptides. This chimeric gene could then be introduced into appropriate microorganisms via transformation to provide high level expression of the encoded protein disulfide isomerases. An example of a vector for high level expression of the instant polypeptides in a bacterial host is provided (Example 7).

All or a substantial portion of the nucleic acid fragments of the instant invention may also be used as probes for genetically and physically mapping the genes that they are a part of, and as markers for traits linked to those genes. Such information may be useful in plant breeding in order to develop lines with desired phenotypes. For example, the instant nucleic acid fragments may be used as restriction fragment length polymorphism (RFLP) markers. Southern blots (Maniatis) of restriction-digested plant genomic DNA may be probed with the nucleic acid fragments of the instant invention. The resulting banding patterns may then be subjected to genetic analyses using computer programs such as MapMaker (Lander et al. (1987) *Genomics 1:174-181*) in order to construct a genetic map. In addition, the nucleic acid fragments of the instant invention may be used to probe Southern blots containing restriction endonuclease-treated genomic DNAs of a set of individuals representing parent and progeny of a defined genetic cross. Segregation of the DNA polymorphisms is noted and used to calculate the position of the instant nucleic acid sequence in the genetic map previously obtained using this population (Botstein et al. (1980) *Am. J. Hum. Genet.* 32:314-331).

The production and use of plant gene-derived probes for use in genetic mapping is described in Bernatzky and Tanksley (1986) *Plant Mol. Biol. Reporter 4:37-41*. Numerous publications describe genetic mapping of specific cDNA clones using the methodology outlined above or variations thereof. For example, F2 intercross populations, backcross populations, randomly mated populations, near isogenic lines, and other sets of individuals may be used for mapping. Such methodologies are well known to those skilled in the art.

Nucleic acid probes derived from the instant nucleic acid sequences may also be used for physical mapping (i.e., placement of sequences on physical maps; *see* Hoheisel et al. In:

*Nonmammalian Genomic Analysis: A Practical Guide*, Academic press 1996, pp. 319-346, and references cited therein).

In another embodiment, nucleic acid probes derived from the instant nucleic acid sequences may be used in direct fluorescence *in situ* hybridization (FISH) mapping (Trask 5 (1991) *Trends Genet.* 7:149-154). Although current methods of FISH mapping favor use of large clones (several to several hundred KB; see Laan et al. (1995) *Genome Res.* 5:13-20), improvements in sensitivity may allow performance of FISH mapping using shorter probes.

A variety of nucleic acid amplification-based methods of genetic and physical mapping may be carried out using the instant nucleic acid sequences. Examples include 10 allele-specific amplification (Kazazian (1989) *J. Lab. Clin. Med.* 11:95-96), polymorphism of PCR-amplified fragments (CAPS; Sheffield et al. (1993) *Genomics* 16:325-332), allele-specific ligation (Landegren et al. (1988) *Science* 241:1077-1080), nucleotide extension reactions (Sokolov (1990) *Nucleic Acid Res.* 18:3671), Radiation Hybrid Mapping (Walter et al. (1997) *Nat. Genet.* 7:22-28) and Happy Mapping (Dear and Cook (1989) *Nucleic Acid 15 Res.* 17:6795-6807). For these methods, the sequence of a nucleic acid fragment is used to design and produce primer pairs for use in the amplification reaction or in primer extension reactions. The design of such primers is well known to those skilled in the art. In methods employing PCR-based genetic mapping, it may be necessary to identify DNA sequence differences between the parents of the mapping cross in the region corresponding to the 20 instant nucleic acid sequence. This, however, is generally not necessary for mapping methods.

## EXAMPLES

The present invention is further defined in the following Examples, in which all parts and percentages are by weight and degrees are Celsius, unless otherwise stated. It should be understood that these Examples, while indicating preferred embodiments of the invention, 25 are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

### EXAMPLE 1

#### Composition of cDNA Libraries: Isolation and Sequencing of cDNA Clones

cDNA libraries representing mRNAs from various balsam pear, corn, rice, soybean and wheat tissues were prepared. The characteristics of the libraries are described below.

TABLE 2  
cDNA Libraries from Balsam Pear, Corn, Rice, Soybean and Wheat

Library	Tissue	Clone
cen3n	Corn Endosperm 20 Days After Pollination*	cen3n.pk0155.e7
cr1n	Corn Root From 7 Day Old Seedlings*	cr1n.pk0090.d2
cs1	Corn Leaf Sheath From 5 Week Old Plant	cs1.pk0077.f10
cs1	Corn Leaf Sheath From 5 Week Old Plant	cs1.pk0100.a7
cs1	Corn Silk	cs1.pk0032.c9
fds	<i>Momordica charantia</i> Developing Seed	fds.pk0022.c11
p0032	Corn Regenerating Callus (Hi-II 223a and 1129e), 10 and 14 Days After Auxin Removal, Pooled	p0032.crcbb52r
p0125	Corn Anther Prophase I*	p0125.czabp07r
scr1c	Soybean Embryogenic Suspension Culture Subjected to 4 Vacuum Cycles and Collected 12 Hours Later	scr1c.pk005.i17
sdp2c	Soybean Developing Pods (6-7 mm)	sdp2c.pk038.e22
sdp3c	Soybean Developing Pods (8-9 mm)	sdp3c.pk021.a3
sfl1	Soybean Immature Flower	sfl1.pk0026.h1
sl2	Soybean Two-Week-Old Developing Seedlings Treated With 2.5 ppm chlormuron	sl2.pk0075.b10
sr1	Soybean Root	sr1.pk0095.e9
srr3c	Soybean 8-Day-Old Root	srr3c.pk002.a8
wl1n	Wheat Leaf From 7 Day Old Seedling*	wl1n.pk0027.f4
wre1n	Wheat Root From 7 Day Old Etiolated Seedling*	wre1n.pk0015.d10

\* These libraries were normalized essentially as described in U.S. Patent No. 5,482,845, incorporated herein by reference.

5

cDNA libraries may be prepared by any one of many methods available. For example, the cDNAs may be introduced into plasmid vectors by first preparing the cDNA libraries in Uni-ZAP™ XR vectors according to the manufacturer's protocol (Stratagene Cloning Systems, La Jolla, CA). The Uni-ZAP™ XR libraries are converted into plasmid 10 libraries according to the protocol provided by Stratagene. Upon conversion, cDNA inserts will be contained in the plasmid vector pBluescript. In addition, the cDNAs may be introduced directly into precut Bluescript II SK(+) vectors (Stratagene) using T4 DNA ligase (New England Biolabs), followed by transfection into DH10B cells according to the manufacturer's protocol (GIBCO BRL Products). Once the cDNA inserts are in plasmid 15 vectors, plasmid DNAs are prepared from randomly picked bacterial colonies containing recombinant pBluescript plasmids, or the insert cDNA sequences are amplified via polymerase chain reaction using primers specific for vector sequences flanking the inserted cDNA sequences. Amplified insert DNAs or plasmid DNAs are sequenced in dye-primer

sequencing reactions to generate partial cDNA sequences (expressed sequence tags or "ESTs"; see Adams et al., (1991) *Science* 252:1651-1656). The resulting ESTs are analyzed using a Perkin Elmer Model 377 fluorescent sequencer.

EXAMPLE 2

Identification of cDNA Clones

5 cDNA clones encoding protein disulfide isomerases were identified by conducting BLAST (Basic Local Alignment Search Tool; Altschul et al. (1993) *J. Mol. Biol.* 215:403-410; see also [www.ncbi.nlm.nih.gov/BLAST/](http://www.ncbi.nlm.nih.gov/BLAST/)) searches for similarity to sequences contained in the BLAST "nr" database (comprising all non-redundant GenBank CDS

10 translations, sequences derived from the 3-dimensional structure Brookhaven Protein Data Bank, the last major release of the SWISS-PROT protein sequence database, EMBL, and DDBJ databases). The cDNA sequences obtained in Example 1 were analyzed for similarity to all publicly available DNA sequences contained in the "nr" database using the BLASTN algorithm provided by the National Center for Biotechnology Information (NCBI). The

15 DNA sequences were translated in all reading frames and compared for similarity to all publicly available protein sequences contained in the "nr" database using the BLASTX algorithm (Gish and States (1993) *Nat. Genet.* 3:266-272) provided by the NCBI. For convenience, the P-value (probability) of observing a match of a cDNA sequence to a sequence contained in the searched databases merely by chance as calculated by BLAST are reported herein as "pLog" values, which represent the negative of the logarithm of the reported P-value. Accordingly, the greater the pLog value, the greater the likelihood that the cDNA sequence and the BLAST "hit" represent homologous proteins.

EXAMPLE 3

Characterization of cDNA Clones Encoding Protein Disulfide Isomerase Precursor

25 The BLASTX search using the EST sequences from clones listed in Table 3 revealed similarity of the polypeptides encoded by the cDNAs to protein disulfide isomerase precursor from *Humicola insolens* or *Bos taurus* (NCBI General Identifier Nos. 1709618 and 129726, respectively). Shown in Table 3 are the BLAST results for individual ESTs ("EST"), or the sequences of the entire cDNA inserts comprising the indicated cDNA clones ("FIS"):

TABLE 3  
BLAST Results for Sequences Encoding Polypeptides Homologous  
to Protein Disulfide Isomerase Precursor

Clone	Status	NCBI General Identifier No.	BLAST pLog Score
cr1n.pk0090.d2	EST	1709618	55.52
srr3c.pk002.a8	EST	1709618	48.52
csi1.pk0032.c9:fis	FIS	129726	28.04

The data in Table 4 represents a calculation of the percent identity of the amino acid sequences set forth in SEQ ID NOS:2, 4 and 6 and the *Humicola insolens* and *Bos taurus* sequences (NCBI General Identifier Nos. 1709618 and 129726, respectively).

5

TABLE 4  
Percent Identity of Amino Acid Sequences Deduced From the Nucleotide Sequences  
of cDNA Clones Encoding Polypeptides Homologous  
to Protein Disulfide Isomerase Precursor

SEQ ID NO.	Percent Identity to	
	1709618	129726
2	80.0	42.7
4	17.0	22.2
6	50.0	37.3

10

Sequence alignments and percent identity calculations were performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS* 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5. Sequence alignments and BLAST scores and probabilities indicate that the nucleic acid fragments comprising the instant cDNA clones encode a substantial portion of two corn and one soybean protein disulfide isomerase precursor. These sequences represent the first corn and soybean sequences encoding protein disulfide isomerase precursor.

#### EXAMPLE 4

##### Characterization of cDNA Clones Encoding RB60

The BLASTX search using the EST sequences from clones listed in Table 5 revealed similarity of the polypeptides encoded by the cDNAs to RB60 from *Chlamydomonas reinhardtii* and to the putative protein disulfide isomerase-like protein from *Arabidopsis thaliana* resulting from the EU Arabidopsis sequencing project (NCBI General Identifier Nos. 2708314 and 4678297, respectively). Shown in Table 5 are the BLAST results for individual ESTs ("EST"), the sequences of the entire cDNA inserts comprising the indicated cDNA clones ("FIS"), or contigs assembled from an FIS and one or more ESTs ("Contig\*"):

TABLE 5

BLAST Results for Sequences Encoding Polypeptides Homologous to RB60

Clone	Status	2708314	BLAST pLog Score
fds.pk0022.c11	FIS	101.00	>254.00
Contig of:	Contig*	95.00	157.00
cen3n.pk0155.e7			
cs1.pk0100.a7			
p0032.crcbb52r			
p0125.czabp07r			
cs1.pk0077.f10	FIS	47.15	83.52
sr1.pk0095.e9	FIS	34.30	31.70
Contig of:	Contig*	105.00	>254.00
scr1c.pk005.i17			
sdp2c.pk038.e22			
sdp3c.pk021.a3			
sfl1.pk0026.h1			
sl2.pk0075.b10			
wl1n.pk0027.f4	EST	58.30	59.09
wre1n.pk0015.d10	FIS	59.00	92.00

The sequences from clones wl1n.pk0027.f4 and sr1.pk0095.e9 also showed similarity

5 to the predicted gene encoded by the contig of the rice ESTs D22477 and AU75323. The data in Table 6 represents a calculation of the percent identity of the amino acid sequences set forth in SEQ ID NOS:8, 10, 12, 14, 16, 18 and 20 and the *Chlamydomonas reinhardtii* and *Arabidopsis thaliana* sequences (NCBI General Identifier Nos. 2708314 and 4678297).

10

TABLE 4

Percent Identity of Amino Acid Sequences Deduced From the Nucleotide Sequences of cDNA Clones Encoding Polypeptides Homologous to RB60

SEQ ID NO.	2708314	Percent Identity to
8	35.5	58.8
10	32.0	47.9
12	39.5	66.4
14	28.3	25.9
16	34.8	57.0
18	27.3	25.9
20	35.4	53.4

Sequence alignments and percent identity calculations were performed using the

15 Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc.,

Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS*. 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3,

5 WINDOW=5 and DIAGONALS SAVED=5. Sequence alignments and BLAST scores and probabilities indicate that the nucleic acid fragments comprising the instant cDNA clones encode a substantial portion of a balsam pear, two corn, two soybean and two wheat RB60. These sequences represent the first balsam pear, corn, soybean and wheat sequences encoding RB60.

10

#### EXAMPLE 5

##### Expression of Chimeric Genes in Monocot Cells

A chimeric gene comprising a cDNA encoding the instant polypeptides in sense orientation with respect to the maize 27 kD zein promoter that is located 5' to the cDNA fragment, and the 10 kD zein 3' end that is located 3' to the cDNA fragment, can be constructed. The cDNA fragment of this gene may be generated by polymerase chain reaction (PCR) of the cDNA clone using appropriate oligonucleotide primers. Cloning sites (NcoI or SmaI) can be incorporated into the oligonucleotides to provide proper orientation of the DNA fragment when inserted into the digested vector pML103 as described below. Amplification is then performed in a standard PCR. The amplified DNA is then digested with restriction enzymes NcoI and SmaI and fractionated on an agarose gel. The appropriate band can be isolated from the gel and combined with a 4.9 kb NcoI-SmaI fragment of the plasmid pML103. Plasmid pML103 has been deposited under the terms of the Budapest Treaty at ATCC (American Type Culture Collection, 10801 University Blvd., Manassas, VA 20110-2209), and bears accession number ATCC 97366. The DNA segment from pML103 contains a 1.05 kb Sall-NcoI promoter fragment of the maize 27 kD zein gene and a 0.96 kb SmaI-Sall fragment from the 3' end of the maize 10 kD zein gene in the vector pGem9Zf(+) (Promega). Vector and insert DNA can be ligated at 15°C overnight, essentially as described (Maniatis). The ligated DNA may then be used to transform *E. coli* XL1-Blue (Epicurian Coli XL-1 Blue™; Stratagene). Bacterial transformants can be screened by restriction enzyme digestion of plasmid DNA and limited nucleotide sequence analysis using the dideoxy chain termination method (Sequenase™ DNA Sequencing Kit; U.S. Biochemical). The resulting plasmid construct would comprise a chimeric gene encoding, in the 5' to 3' direction, the maize 27 kD zein promoter, a cDNA fragment encoding the instant polypeptides, and the 10 kD zein 3' region.

35

The chimeric gene described above can then be introduced into corn cells by the following procedure. Immature corn embryos can be dissected from developing caryopses derived from crosses of the inbred corn lines H99 and LH132. The embryos are isolated 10 to 11 days after pollination when they are 1.0 to 1.5 mm long. The embryos are then placed

with the axis-side facing down and in contact with agarose-solidified N6 medium (Chu et al. (1975) *Sci. Sin. Peking* 18:659-668). The embryos are kept in the dark at 27°C. Friable embryogenic callus consisting of undifferentiated masses of cells with somatic proembryoids and embryoids borne on suspensor structures proliferates from the scutellum of these immature embryos. The embryogenic callus isolated from the primary explant can be cultured on N6 medium and sub-cultured on this medium every 2 to 3 weeks.

5 The plasmid, p35S/Ac (obtained from Dr. Peter Eckes, Hoechst Ag, Frankfurt, Germany) may be used in transformation experiments in order to provide for a selectable marker. This plasmid contains the *Pat* gene (see European Patent Publication 0 242 236)

10 which encodes phosphinothricin acetyl transferase (PAT). The enzyme PAT confers resistance to herbicidal glutamine synthetase inhibitors such as phosphinothricin. The *pat* gene in p35S/Ac is under the control of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*.

15 The particle bombardment method (Klein et al. (1987) *Nature* 327:70-73) may be used to transfer genes to the callus culture cells. According to this method, gold particles (1 µm in diameter) are coated with DNA using the following technique. Ten µg of plasmid DNAs are added to 50 µL of a suspension of gold particles (60 mg per mL). Calcium chloride (50 µL of a 2.5 M solution) and spermidine free base (20 µL of a 1.0 M solution) are added to the particles. The suspension is vortexed during the addition of these solutions. After 20 10 minutes, the tubes are briefly centrifuged (5 sec at 15,000 rpm) and the supernatant removed. The particles are resuspended in 200 µL of absolute ethanol, centrifuged again and the supernatant removed. The ethanol rinse is performed again and the particles resuspended in a final volume of 30 µL of ethanol. An aliquot (5 µL) of the DNA-coated gold particles can be placed in the center of a Kapton™ flying disc (Bio-Rad Labs). The particles are then accelerated into the corn tissue with a Biolistic™ PDS-1000/He (Bio-Rad Instruments, Hercules CA), using a helium pressure of 1000 psi, a gap distance of 0.5 cm and a flying distance of 1.0 cm.

25 For bombardment, the embryogenic tissue is placed on filter paper over agarose-solidified N6 medium. The tissue is arranged as a thin lawn and covered a circular area of about 5 cm in diameter. The petri dish containing the tissue can be placed in the chamber of the PDS-1000/He approximately 8 cm from the stopping screen. The air in the chamber is then evacuated to a vacuum of 28 inches of Hg. The macrocarrier is accelerated with a helium shock wave using a rupture membrane that bursts when the He pressure in the shock tube reaches 1000 psi.

30 Seven days after bombardment the tissue can be transferred to N6 medium that contains gluphosinate (2 mg per liter) and lacks casein or proline. The tissue continues to grow slowly on this medium. After an additional 2 weeks the tissue can be transferred to

fresh N6 medium containing glufosinate. After 6 weeks, areas of about 1 cm in diameter of actively growing callus can be identified on some of the plates containing the glufosinate-supplemented medium. These calli may continue to grow when sub-cultured on the selective medium.

5 Plants can be regenerated from the transgenic callus by first transferring clusters of tissue to N6 medium supplemented with 0.2 mg per liter of 2,4-D. After two weeks the tissue can be transferred to regeneration medium (Fromm et al. (1990) *Bio/Technology* 8:833-839).

#### EXAMPLE 6

##### Expression of Chimeric Genes in Dicot Cells

10 A seed-specific expression cassette composed of the promoter and transcription terminator from the gene encoding the  $\beta$  subunit of the seed storage protein phaseolin from the bean *Phaseolus vulgaris* (Doyle et al. (1986) *J. Biol. Chem.* 261:9228-9238) can be used for expression of the instant polypeptides in transformed soybean. The phaseolin cassette

15 includes about 500 nucleotides upstream (5') from the translation initiation codon and about 1650 nucleotides downstream (3') from the translation stop codon of phaseolin. Between the 5' and 3' regions are the unique restriction endonuclease sites *Nco* I (which includes the ATG translation initiation codon), *Sma* I, *Kpn* I and *Xba* I. The entire cassette is flanked by *Hind* III sites.

20 The cDNA fragment of this gene may be generated by polymerase chain reaction (PCR) of the cDNA clone using appropriate oligonucleotide primers. Cloning sites can be incorporated into the oligonucleotides to provide proper orientation of the DNA fragment when inserted into the expression vector. Amplification is then performed as described above, and the isolated fragment is inserted into a pUC18 vector carrying the seed expression cassette.

25 Soybean embryos may then be transformed with the expression vector comprising sequences encoding the instant polypeptides. To induce somatic embryos, cotyledons, 3-5 mm in length dissected from surface sterilized, immature seeds of the soybean cultivar A2872, can be cultured in the light or dark at 26°C on an appropriate agar medium for 6-10 weeks. Somatic embryos which produce secondary embryos are then excised and placed into a suitable liquid medium. After repeated selection for clusters of somatic embryos which multiplied as early, globular staged embryos, the suspensions are maintained as described below.

30 Soybean embryogenic suspension cultures can be maintained in 35 mL liquid media on a rotary shaker, 150 rpm, at 26°C with fluorescent lights on a 16:8 hour day/night schedule. Cultures are subcultured every two weeks by inoculating approximately 35 mg of tissue into 35 mL of liquid medium.

Soybean embryogenic suspension cultures may then be transformed by the method of particle gun bombardment (Klein et al. (1987) *Nature* (London) 327:70-73, U.S. Patent

- No. 4,945,050). A DuPont Biolistic™ PDS1000/HE instrument (helium retrofit) can be used for these transformations.

5 A selectable marker gene which can be used to facilitate soybean transformation is a chimeric gene composed of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812), the hygromycin phosphotransferase gene from plasmid pJR225 (from *E. coli*; Gritz et al. (1983) *Gene* 25:179-188) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*. The seed expression 10 cassette comprising the phaseolin 5' region, the fragment encoding the instant polypeptides and the phaseolin 3' region can be isolated as a restriction fragment. This fragment can then be inserted into a unique restriction site of the vector carrying the marker gene.

To 50  $\mu$ L of a 60 mg/mL 1  $\mu$ m gold particle suspension is added (in order): 5  $\mu$ L DNA (1  $\mu$ g/ $\mu$ L), 20  $\mu$ L spermidine (0.1 M), and 50  $\mu$ L  $\text{CaCl}_2$  (2.5 M). The particle

15 preparation is then agitated for three minutes, spun in a microfuge for 10 seconds and the supernatant removed. The DNA-coated particles are then washed once in 400  $\mu$ L 70% ethanol and resuspended in 40  $\mu$ L of anhydrous ethanol. The DNA/particle suspension can be sonicated three times for one second each. Five  $\mu$ L of the DNA-coated gold particles are then loaded on each macro carrier disk.

20 Approximately 300-400 mg of a two-week-old suspension culture is placed in an empty 60x15 mm petri dish and the residual liquid removed from the tissue with a pipette. For each transformation experiment, approximately 5-10 plates of tissue are normally bombarded. Membrane rupture pressure is set at 1100 psi and the chamber is evacuated to a vacuum of 28 inches mercury. The tissue is placed approximately 3.5 inches away from the retaining screen and bombarded three times. Following bombardment, the tissue can be divided in half and placed back into liquid and cultured as described above.

25 Five to seven days post bombardment, the liquid media may be exchanged with fresh media, and eleven to twelve days post bombardment with fresh media containing 50 mg/mL hygromycin. This selective media can be refreshed weekly. Seven to eight weeks post bombardment, green, transformed tissue may be observed growing from untransformed, necrotic embryogenic clusters. Isolated green tissue is removed and inoculated into individual flasks to generate new, clonally propagated, transformed embryogenic suspension cultures. Each new line may be treated as an independent transformation event. These suspensions can then be subcultured and maintained as clusters of immature embryos or 35 regenerated into whole plants by maturation and germination of individual somatic embryos.

EXAMPLE 7

Expression of Chimeric Genes in Microbial Cells

The cDNAs encoding the instant polypeptides can be inserted into the T7 *E. coli* expression vector pBT430. This vector is a derivative of pET-3a (Rosenberg et al. (1987) *Gene* 56:125-135) which employs the bacteriophage T7 RNA polymerase/T7 promoter system. Plasmid pBT430 was constructed by first destroying the EcoR I and Hind III sites in pET-3a at their original positions. An oligonucleotide adaptor containing EcoR I and Hind III sites was inserted at the BamH I site of pET-3a. This created pET-3aM with additional unique cloning sites for insertion of genes into the expression vector. Then, the 10 Nde I site at the position of translation initiation was converted to an Nco I site using oligonucleotide-directed mutagenesis. The DNA sequence of pET-3aM in this region, 5'-CATATGG, was converted to 5'-CCCATGG in pBT430.

Plasmid DNA containing a cDNA may be appropriately digested to release a nucleic acid fragment encoding the protein. This fragment may then be purified on a 1% NuSieve 15 GTG™ low melting agarose gel (FMC). Buffer and agarose contain 10 µg/ml ethidium bromide for visualization of the DNA fragment. The fragment can then be purified from the agarose gel by digestion with GELase™ (Epicentre Technologies) according to the manufacturer's instructions, ethanol precipitated, dried and resuspended in 20 µL of water. Appropriate oligonucleotide adapters may be ligated to the fragment using T4 DNA ligase 20 (New England Biolabs, Beverly, MA). The fragment containing the ligated adapters can be purified from the excess adapters using low melting agarose as described above. The vector pBT430 is digested, dephosphorylated with alkaline phosphatase (NEB) and deproteinized with phenol/chloroform as described above. The prepared vector pBT430 and fragment can then be ligated at 16°C for 15 hours followed by transformation into DH5 electrocompetent 25 cells (GIBCO BRL). Transformants can be selected on agar plates containing LB media and 100 µg/mL ampicillin. Transformants containing the gene encoding the instant polypeptides are then screened for the correct orientation with respect to the T7 promoter by restriction enzyme analysis.

For high level expression, a plasmid clone with the cDNA insert in the correct 30 orientation relative to the T7 promoter can be transformed into *E. coli* strain BL21(DE3) (Studier et al. (1986) *J. Mol. Biol.* 189:113-130). Cultures are grown in LB medium containing ampicillin (100 mg/L) at 25°C. At an optical density at 600 nm of approximately 1, IPTG (isopropylthio-β-galactoside, the inducer) can be added to a final concentration of 0.4 mM and incubation can be continued for 3 h at 25°. Cells are then harvested by 35 centrifugation and re-suspended in 50 µL of 50 mM Tris-HCl at pH 8.0 containing 0.1 mM DTT and 0.2 mM phenyl methylsulfonyl fluoride. A small amount of 1 mm glass beads can be added and the mixture sonicated 3 times for about 5 seconds each time with a microprobe sonicator. The mixture is centrifuged and the protein concentration of the supernatant

determined. One  $\mu$ g of protein from the soluble fraction of the culture can be separated by SDS-polyacrylamide gel electrophoresis. Gels can be observed for protein bands migrating at the expected molecular weight.

CLAIMS

What is claimed is:

1. A composition comprising an isolated polynucleotide comprising a nucleotide sequence encoding a first polypeptide of at least 100 amino acids that has at least 85% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of a polypeptide of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, and 20, or an isolated polynucleotide comprising the complement of the nucleotide sequence.

5 2. The composition of Claim 1, wherein the isolated nucleotide sequence consists of a nucleic acid sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 10 11, 13, 15, 17, and 19 that codes for the polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, and 20.

15 3. The composition of Claim 1 wherein the isolated polynucleotide is DNA.

4. The composition of Claim 1 wherein the isolated polynucleotide is RNA.

5. A chimeric gene comprising the isolated polynucleotide of Claim 1 operably

15 linked to suitable regulatory sequences.

6. An isolated host cell comprising the chimeric gene of Claim 5 or the isolated polynucleotide of Claim 1.

7. An isolated host cell comprising an isolated polynucleotide of Claim 1.

8. The isolated host cell of Claim 7 wherein the isolated host selected from the 20 group consisting of yeast, bacteria, plant, and virus.

9. A virus comprising the isolated polynucleotide of Claim 1.

10. A composition comprising a polypeptide of at least 100 amino acids that has at least 85% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of a polypeptide of SEQ ID NOs:2, 4, 6, 8, 20 10, 12, 14, 16, 18, and 20.

11. A method of selecting an isolated polynucleotide that affects the level of expression of a polypeptide in a plant cell, the method comprising the steps of:

30 constructing an isolated polynucleotide comprising a nucleotide sequence of at least one of 30 contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, and the complement of such nucleotide sequences;

introducing the isolated polynucleotide into a plant cell; and measuring the level of a polypeptide in the plant cell containing the polynucleotide.

12. The method of Claim 11 wherein the isolated polynucleotide consists of a

35 nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, and 19 that codes for the polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, and 20.

13. A method of selecting an isolated polynucleotide that affects the level of expression of polypeptide in a plant cell, the method comprising the steps of:

- constructing an isolated polynucleotide of Claim 1;
- introducing the isolated polynucleotide into a plant cell; and
- measuring the level of polypeptide in the plant cell containing the polynucleotide.

14. A method of obtaining a nucleic acid fragment encoding a polypeptide comprising the steps of:

- synthesizing an oligonucleotide primer comprising a nucleotide sequence of at least one of 40 contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, and the complement of such nucleotide sequences; and
- amplifying a nucleic acid sequence using the oligonucleotide primer.

15. A method of obtaining a nucleic acid fragment encoding the amino acid sequence encoding a protein disulfide isomerase polypeptide comprising the steps of:

- probing a cDNA or genomic library with an isolated polynucleotide comprising a nucleotide sequence of at least one of 30 contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, and the complement of such nucleotide sequences; and
- identifying a DNA clone that hybridizes with the isolated polynucleotide.

TITLE

PLANT PROTEIN DISULFIDE ISOMERASES

ABSTRACT OF THE DISCLOSURE

This invention relates to an isolated nucleic acid fragment encoding a protein

5 disulfide isomerase. The invention also relates to the construction of a chimeric gene  
encoding all or a portion of the protein disulfide isomerase, in sense or antisense orientation,  
wherein expression of the chimeric gene results in production of altered levels of the protein  
disulfide isomerase in a transformed host cell.

10

15

20

25

30

35

GJF/bjm

## DECLARATION and POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

## PLANT PROTEIN DISULFIDE ISOMERASES

the specification of which is attached hereto unless the following box is checked:

was filed on \_\_\_\_\_ as U.S. Application No. \_\_\_\_\_ or PCT International Application No. \_\_\_\_\_ and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is known to me to be material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Application No.	Country	Filing Date	Priority Claimed (Yes/No)
-----------------	---------	-------------	---------------------------

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States Provisional Application(s) listed below.

U.S. Provisional Application No.	U.S. Filing Date
60/104,426	10/15/98

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International Application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application or PCT International Application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is known to me to be material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application No.	Filing Date	Status (patented, pending or abandoned)
-----------------	-------------	---

**POWER OF ATTORNEY:** I hereby appoint the following attorney(s) and/or agent(s) the power to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

Name: GREGORY J. FEULNER	Registration No.: 41,744
--------------------------	--------------------------

Send correspondence and direct telephone calls to:  GREGORY J. FEULNER	E. I. du Pont de Nemours and Company Legal - Patents Wilmington, DE 19898, U.S.A.	Tel. No. (302) 992-3749  Fax No. (302) 892-7949
--	---	---

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 101 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

## INVENTOR(S)

Full Name of Inventor	Last Name CAHOON	First Name REBECCA	Middle Name E. Date:	
Signature (please sign full name):				
Residence & Citizenship	City WILMINGTON	State or Foreign Country DELWARE	Country of Citizenship U.S.A.	
Post Office Address	Post Office Address 2331 WEST 18TH STREET	City WILMINGTON	State or Country DELWARE	Zip Code 19806
Full Name of Inventor	Last Name MIAO	First Name GUO-HUA	Middle Name	
Signature (please sign full name):				
Residence & Citizenship	City HOCKESSIN	State or Foreign Country DELWARE	Country of Citizenship PEOPLES REPUBLIC OF CHINA	
Post Office Address	Post Office Address 202 CHERRY BLOSSUM PLACE	City HOCKESSIN	State or Country DELWARE	Zip Code 19707
Full Name of Inventor	Last Name HERRMANN	First Name RAFAEL	Middle Name	
Signature (please sign full name):				
Residence & Citizenship	City WILMINGTON	State or Foreign Country DELWARE	Country of Citizenship ISRAEL	
Post Office Address	Post Office Address 3120 NAAMANS ROAD	City WILMINGTON	State or Country DELWARE	Zip Code 19810

Full Name of Inventor	Last Name <b>RAFALSKI</b> Signature (please sign full name):	First Name <b>J.</b>	Middle Name <b>ANTONI</b> Date:
Residence & Citizenship	City <b>WILMINGTON</b>	State or Foreign Country <b>DELAWARE</b>	Country of Citizenship <b>U.S.A.</b>
Post Office Address	Post Office Address <b>2028 LONGCOME DRIVE</b>	City <b>WILMINGTON</b>	State or Country <b>DELAWARE</b> Zip Code <b>19810</b>
Full Name of Inventor	Last Name <b>MCCUTCHEON</b> Signature (please sign full name):	First Name <b>BILLY</b>	Middle Name <b>F.</b> Date:
Residence & Citizenship	City <b>NEWARK</b>	State or Foreign Country <b>DELAWARE</b>	Country of Citizenship <b>U.S.A.</b>
Post Office Address	Post Office Address <b>421 CHRISTIANA MILLS DRIVE</b>	City <b>NEWARK</b>	State or Country <b>DELAWARE</b> Zip Code <b>19808</b>

SEQUENCE LISTING

<110> Cahoon, Rebecca E.  
Miao, Guo-Hua  
Herrman, Rafael  
Rafalski, Antoni  
McCutchen, Bill F.

<120> Plant Protein Disulfide Isomerase

<130> BB1085 US NA

<140>

<141>

<150> 60/049,408  
<151> 1998-10-15

<160> 20

<170> Microsoft Office 97

<210> 1  
<211> 504  
<212> DNA  
<213> Zea mays

<220>

<221> unsure  
<222> (463)

<220>

<221> unsure  
<222> (469)

<220>

<221> unsure  
<222> (471)

<220>

<221> unsure  
<222> (496)

<400> 1  
tgccctgcct gtccctgtctt gttcagcgga accttcttt tgggttttat aggttacccc 60  
gtcaaaaaga cagcccatca tgccacccaa gaagatcgcc tgcagttca tggctgtct 120  
ggctgcctat ggctctgtcg ccgactcaga tggctcatcg cttaaccaagg acaccccttgc 180  
ggagtttgc aagtccaaaca attcgttctt cgctgagttc tttgtctccct ggtcggtca 240  
ctgcaaggcc ctgcggccccc agtacggagga ggccggccaccc actctcaagg aqaagaacat 300  
caagcttgc aagatgtact gcaactggagga gtccgacccctc tgccaaagaccc agggcggtca 360  
gggttacccc accctcaagg tcttccgtgg ttttgacat gtcaactccctt actctggcca 420  
gcgttaaggcc gctggatca ttctcacatga ttaagagttc ctncccgng nttcattttta 480  
caaaggaaac cctcgnnggt tttaa 504

<210> 2  
<211> 110  
<212> PRT  
<213> Zea mays

<400> 2  
 Met Ala Ala Leu Ala Ala Tyr Ala Ser Ala Ala Asp Ser Asp Val His  
 1 5 10 15  
 Gln Leu Thr Lys Asp Thr Phe Glu Glu Phe Val Lys Ser Asn Asn Leu  
 20 25 30  
 Val Leu Ala Glu Phe Ala Pro Trp Cys Gly His Cys Lys Ala Leu  
 35 40 45  
 Ala Pro Glu Tyr Glu Glu Ala Ala Thr Thr Leu Lys Glu Lys Asn Ile  
 50 55 60  
 Lys Leu Ala Lys Ile Asp Cys Thr Glu Glu Ser Asp Leu Cys Lys Asp  
 65 70 75 80  
 Gln Gly Val Glu Gly Tyr Pro Thr Leu Lys Val Phe Arg Gly Leu Asp  
 85 90 95  
 Asn Val Thr Pro Tyr Ser Gly Gln Arg Lys Ala Ala Gly Ile  
 100 105 110

<210> 3  
 <211> 505  
 <212> DNA  
 <213> Glycine max

<220>  
 <221> unsure  
 <222> (503)

<400> 3  
 tctttcgtt actccacccgt gtattgtgt tgaagatcgta aataccaaata aaaattatgt 60  
 ttatccacaa gctaataatggaa ttactaagaat tgcatatcggt gcacattttac aaggttatgt 120  
 tggatgttca cttcaacccca ctgtcaaatc tgaagaaatcc cccggaaaaac aagatggcc 180  
 agttttatgtta ctccgtggta aaaaatttgtt atccattgtt atggatgaaa ctaaagatgt 240  
 attatgttgaat ttatgttcaac catgggtgtt acattgttaaa acattatgcctt cccaaatccca 300  
 tgcatatgttgaatcatccca agtccaaatccca caatgttcaat ttggccaaaga ttgatggcc 360  
 tggatgttcaatccgttggat ttatccaaatggttccat attatgttcaat ttggccaaatggcc 420  
 taataagaaa aatccaaatcaatcatatggaaat tggatgttcaat ttggccaaatggcc 480  
 tggatgttcaatccgttggat ttatccaaatggttccat attatgttcaat ttggccaaatggcc 505

<210> 4  
 <211> 158  
 <212> PRT  
 <213> Glycine max

<400> 4  
 Pro Gly Ile Val Val Glu Asp Arg Asn Thr Asn Lys Asn Tyr Val Tyr  
 1 5 10 15

Pro Gln Ala Asn Glu Ile Thr Glu Asp Ala Leu Arg Ala His Leu Gln  
 20 25 30

Gly Tyr Val Asp Gly Thr Leu Gln Pro Thr Val Lys Ser Glu Glu Ile  
 35 40 45

Pro Glu Lys Gln Asp Gly Pro Val Tyr Val Leu Val Gly Lys Asn Phe  
 50 55 60

Glu Ser Ile Val Met Asp Glu Thr Lys Asp Val Leu Val Glu Phe Tyr  
65 70 75 80

Ala Pro Trp Cys Gly His Cys Lys Thr Leu Ala Pro Lys Tyr Asp Ala  
85 90 95

Leu Gly Glu Ser Phe Lys Ser Asn Pro Asn Val Ile Ile Ala Lys Ile  
 100 105 110

Asp Ala Thr Ala Asn Asp Thr Pro Val Asp Ile Gln Gly Phe Pro Thr  
 115 120 125

Ile Ile Tyr Trp Pro Ala Asn Asn Lys Lys Asn Pro Ile Thr Tyr Glu  
 130 135 140

Gly Glu Arg Thr Glu Ser Ala Leu Ala Ala Phe Val Arg Glu  
145 150 155

<210> 5  
<211> 1692  
<212> DNA  
<213> Zea mays

<210> 6  
<211> 418  
<212> PRT  
<213> Zea mays

<400> 6  
 Met Ala Thr Arg Val Leu Pro Pro Ala Leu Leu Ser Phe Ile Leu Leu  
 1 5 10 15  
 Leu Leu Leu Ser Leu Ser Ala Arg Asp Thr Val Ala Ala Gly Glu Asp  
 20 25 30  
 Phe Pro Arg Asp Gly Arg Val Ile Asp Leu Asp Asp Ser Asn Phe Glu  
 35 40 45  
 Ala Ala Leu Gly Ala Ile Asp Phe Leu Phe Val Asp Phe Tyr Ala Pro  
 50 55 60  
 Trp Cys Gly His Cys Lys Arg Leu Ala Pro Glu Leu Asp Glu Ala Ala  
 65 70 75 80  
 Pro Val Leu Ser Gly Leu Ser Glu Pro Ile Val Val Ala Lys Val Asn  
 85 90 95  
 Ala Asp Lys Tyr Arg Lys Leu Gly Ser Lys Tyr Gly Val Asp Gly Phe  
 100 105 110  
 Pro Thr Leu Met Leu Phe Ile His Gly Val Pro Ile Glu Tyr Thr Gly  
 115 120 125  
 Ser Arg Lys Ala Asp Gln Leu Val Arg Asn Leu Lys Lys Phe Val Ser  
 130 135 140  
 Pro Asp Val Ser Ile Leu Glu Ser Asp Ser Ala Ile Lys Asn Phe Val  
 145 150 155 160  
 Glu Asn Ala Gly Ile Ser Phe Pro Ile Phe Leu Gly Phe Gly Val Asn  
 165 170 175  
 Asp Ser Leu Ile Ala Glu Tyr Gly Arg Lys Tyr Lys Lys Arg Ala Trp  
 180 185 190  
 Phe Ala Val Ala Lys Asp Phe Ser Glu Asp Ile Met Val Ala Tyr Glu  
 195 200 205  
 Phe Asp Lys Val Pro Ala Leu Val Ala Ile His Pro Lys Tyr Lys Glu  
 210 215 220  
 Gln Ser Leu Phe Tyr Gly Pro Phe Glu Glu Asn Phe Leu Glu Asp Phe  
 225 230 235 240  
 Val Arg Gln Ser Leu Leu Pro Leu Val Val Pro Ile Asn Thr Glu Thr  
 245 250 255  
 Leu Lys Met Leu Asn Asp Asp Gln Arg Lys Val Val Leu Thr Ile Leu  
 260 265 270  
 Glu Asp Asp Ser Asp Glu Asn Ser Thr Gln Leu Val Lys Ile Leu Arg  
 275 280 285  
 Ser Ala Ala Asn Ala Asn Arg Asp Leu Val Phe Gly Tyr Val Gly Ile  
 290 295 300  
 Lys Gln Trp Asp Gly Phe Val Glu Thr Phe Asp Val Ser Lys Ser Ser  
 305 310 315 320

Gln Leu Pro Lys Leu Leu Val Trp Asp Arg Asp Glu Glu Tyr Glu Leu  
 325 330 335

Val Asp Gly Ser Glu Arg Leu Glu Glu Gly Asp Gln Ala Ser Gln Ile  
 340 345 350

Ser Gln Phe Leu Glu Gly Tyr Arg Ala Gly Arg Thr Thr Lys Lys Lys  
 355 360 365

Ile Thr Gly Pro Ser Phe Met Gly Phe Leu Asn Ser Leu Val Ser Leu  
370 375 380

Asn Ser Leu Tyr Ile Leu Ile Phe Val Ile Ala Leu Leu Phe Val Met  
 385 390 395 400

Val Tyr Phe Ala Gly Gln Asp Asp Thr Pro Gln Pro Arg Arg Ile His  
405 410 415

Glu Glu

<210> 8  
<211> 541  
<212> PRT  
<213> Momordica charantia

<400> 8  
His Glu Glu Pro Asp Ala Ala Ala Gly Ala Ser Ala His Arg His Leu  
1 5 10 15  
Pro Asp Phe Asp Gly Phe Glu Gly Gly Ala Glu Asp Glu Asp Phe Gly  
20 25 30  
Asp Phe Ser Asp Phe Glu Asp Ser Asp Ala Asp Arg Asp Glu Tyr Lys  
35 40 45  
Ala Pro Glu Val Asp Glu Lys Asp Val Val Val Leu Lys Glu Gly Asn  
50 55 60  
Phe Ser Asp Phe Val Glu Lys Asn Arg Phe Val Met Val Glu Phe Tyr  
65 70 75 80  
Ala Pro Trp Cys Gly His Cys Gln Ala Leu Ala Pro Glu Tyr Ala Ala  
85 90 95  
Ala Ala Thr Glu Leu Lys Gly Glu Asn Val Val Leu Ala Lys Val Asp  
100 105 110  
Ala Thr Glu Glu Asn Glu Leu Ser Gln Lys Tyr Asp Val Gln Gly Phe  
115 120 125  
Pro Thr Val Tyr Phe Phe Ala Asp Gly Val His Lys Ser Tyr Pro Gly  
130 135 140  
Gln Arg Thr Lys Asp Ala Ile Val Thr Trp Ile Lys Lys Lys Ile Gly  
145 150 155 160  
Pro Gly Ile Tyr Asn Ile Thr Ser Val Glu Asp Ala Glu Arg Ile Leu  
165 170 175  
Thr Ser Glu Thr Lys Val Val Leu Gly Tyr Leu Asn Ser Leu Val Gly  
180 185 190  
Pro Glu Ser Asn Glu Leu Ala Ala Ser Arg Leu Glu Asp Asp Val  
195 200 205  
Asn Phe Tyr Gln Thr Val Asp Pro Glu Val Ala Lys Leu Phe His Ile  
210 215 220  
Glu Ala Ser Ala Lys Arg Pro Ala Leu Val Leu Leu Lys Lys Glu Ala  
225 230 235 240  
Glu Lys Leu Asn Arg Phe Asp Gly Glu Phe Ser Lys Ser Ala Ile Ala  
245 250 255  
Glu Phe Val Phe Ala Asn Lys Leu Pro Leu Val Thr Lys Phe Thr Arg  
260 265 270  
Glu Ser Ala Pro Leu Ile Phe Glu Ser Ser Ile Lys Lys Gln Leu Ile  
275 280 285

Leu Phe Ala Ile Ser Asn Asp Ser Glu Lys Leu Ile Pro Ile Phe Glu  
290 295 300

Glu Ser Ser Lys Ser Phe Lys Gly Lys Leu Ile Phe Val Tyr Val Glu  
305 310 315 320

Ile Asp Asn Glu Asp Val Gly Lys Pro Val Ser Glu Tyr Phe Gly Ile  
325 330 335

Ser Gly Asn Gly Pro Glu Val Leu Gly Tyr Thr Gly Asn Glu Asp Ser  
340 345 350

Lys Lys Phe Val Leu Ala Lys Glu Val Thr Leu Asp Asn Ile Lys Ala  
355 360 365

Phe Gly Glu Asn Phe Leu Glu Asp Lys Leu Lys Pro Phe Tyr Lys Ser  
370 375 380

Asp Pro Ile Pro Glu Thr Asn Asp Gly Asp Val Lys Val Val Val Gly  
385 390 395 400

Asp Asn Phe Asp Asn Ile Val Leu Asp Glu Ser Lys Asp Val Leu Leu  
405 410 415

Glu Ile Tyr Ala Pro Trp Cys Gly His Cys Gln Ala Leu Glu Pro Thr  
420 425 430

Tyr Asn Lys Leu Ala Lys His Leu Arg Gly Ile Asp Ser Leu Val Ile  
435 440 445

Ala Lys Met Asp Gly Thr Thr Asn Glu His Pro Arg Ala Lys Ser Asp  
450 455 460

Gly Phe Pro Thr Ile Leu Phe Phe Pro Ala Gly Asn Lys Ser Phe Asp  
465 470 475 480

Pro Ile Thr Val Asp Thr Asp Arg Thr Val Val Ala Leu Tyr Lys Phe  
485 490 495

Ile Lys Lys Asn Ala Ser Ile Pro Phe Lys Leu Gln Lys Pro Val Ser  
500 505 510

Ser Pro Lys Ala Val Ser Ser Glu Ala Lys Ser Gly Asp Ala Lys Glu  
515 520 525

Ser Pro Lys Ser Ser Thr Thr Asp Val Lys Asp Glu Leu  
530 535 540

<210> 9

<211> 2031

<212> DNA

<213> Zea mays

<400> 9

ctcaccagct gcccgcgcac ccaattccctc tcgctggacg gctgcagcac atcatcagggt 60  
gagaccgtga gagggaaatgg gatcaaacac aatgtccctc ccatctttc ccgtcgctct 120  
cctgtcttc ctccctcgccca ccatacgccgc agccgcgcga agcaacatgg atgaggagggt 180  
ggtggacac ctccagatcttattgacaa ctccgcacgac atccccacca acgtatccgaa 240  
cgggtggct gagggagact acgacgcacga cgaccttctc ttccaagatc aggaccagga 300  
cttcacacggc caccagccgg agatgcacga gacccacgta gtggtcctcg ccggccgcaaa 360

<210> 10  
<211> 570  
<212> PRT  
<213> Zea mays

<400> 10  
Met Gly Ser Thr Thr Met Ser Pro Pro Ser Phe Pro Val Val Leu Leu  
1 5 10 15

Leu Leu Leu Leu Ala Thr Ile Ala Ala Ala Ala Gly Ser Asn Met Asp  
20 25 30

Glu Glu Val Val Asp Asp Leu Gln Tyr Leu Ile Asp Asn Ser Asp Asp  
 35 40 45

Ile Pro Thr Asn Asp Pro Asp Gly Trp Pro Glu Gly Asp Tyr Asp Asp  
 50 55 60

Asp Asp Leu Leu Phe Gln Asp Gln Asp Gln Asp Leu Thr Gly His Gln  
65 70 75 80

Pro Glu Ile Asp Glu Thr His Val Val Val Leu Ala Ala Ala Asn Phe  
85 90 95

Ser Ser Phe Leu Ala Ser Ser His His Val Met Val Glu Phe Tyr Ala  
100 105 110

Pro Trp Cys Gly His Cys Gln Glu Leu Ala Pro Gly Leu Ser Arg Arg  
115 120 125

Arg Ala His Leu Ala Gly Ser Thr Asn Gln Pro Arg Pro Asn Phe Ala  
 130 135 140  
 Leu Ala Lys Val Asp Ala Thr Glu Glu Thr Asp Leu Ala Gln Lys Tyr  
 145 150 155 160  
 Asp Val Gln Gly Phe Pro Thr Ile Leu Phe Phe Ile Asp Gly Val Pro  
 165 170 175  
 Arg Gly Tyr Asn Gly Ala Arg Thr Lys Glu Ala Ile Val Asp Trp Ile  
 180 185 190  
 Asn Lys Lys Leu Gly Pro Ala Val Gln Asn Val Thr Ser Val Asp Glu  
 195 200 205  
 Ala Gln Ser Ile Leu Thr Gly Asp Asp Lys Ala Val Leu Ala Phe Leu  
 210 215 220  
 Asp Thr Leu Ser Gly Ala His Ser Asp Glu Leu Ala Ala Ala Ser Arg  
 225 230 235 240  
 Leu Glu Asp Ser Ile Asn Phe Tyr Gln Thr Ser Thr Pro Asp Val Ala  
 245 250 255  
 Lys Leu Phe His Ile Asp Ala Ala Ala Lys Arg Pro Ser Val Val Leu  
 260 265 270  
 Leu Lys Lys Glu Glu Lys Leu Thr Phe Tyr Asp Gly Glu Phe Lys  
 275 280 285  
 Ala Ser Ala Ile Ala Gly Phe Val Ser Ala Asn Lys Leu Pro Leu Val  
 290 295 300  
 Thr Thr Leu Thr Gln Glu Thr Ser Pro Ser Ile Phe Gly Asn Pro Ile  
 305 310 315 320  
 Lys Lys Gln Ile Leu Leu Phe Ala Val Ala Ser Glu Ser Thr Lys Phe  
 325 330 335  
 Leu Pro Ile Phe Lys Glu Ala Ala Lys Pro Phe Lys Gly Lys Leu Leu  
 340 345 350  
 Phe Val Phe Val Glu Arg Asp Ser Glu Glu Val Gly Glu Pro Val Ala  
 355 360 365  
 Asp Tyr Phe Gly Ile Thr Gly Gln Glu Thr Thr Val Leu Ala Tyr Thr  
 370 375 380  
 Gly Asn Glu Asp Ala Arg Lys Phe Phe Leu Asp Gly Glu Val Ser Leu  
 385 390 395 400  
 Glu Ala Ile Lys Asp Phe Ala Glu Gly Phe Leu Glu Asp Lys Leu Thr  
 405 410 415  
 Pro Phe Tyr Lys Ser Glu Pro Val Pro Glu Ser Asn Asp Gly Asp Val  
 420 425 430  
 Lys Ile Val Val Gly Lys Asn Leu Asp Leu Ile Val Phe Asp Glu Thr  
 435 440 445

Lys Asp Val Leu Leu Glu Ile Tyr Ala Pro Trp Cys Gly His Cys Gln  
 450 455 460

Ser Leu Glu Pro Thr Tyr Asn Asn Leu Ala Lys His Leu Arg Ser Val  
465 470 475 480

Asp Ser Leu Val Val Ala Lys Met Asp Gly Thr Thr Asn Glu His Pro  
485 490 495

Arg Ala Lys Ser Asp Gly Tyr Pro Thr Ile Leu Phe Tyr Pro Ala Gly  
 500 505 510

Lys Lys Ser Phe Glu Pro Ile Thr Phe Glu Gly Glu Arg Thr Val Val  
 515 520 525

Asp Leu Tyr Lys Phe Ile Lys Lys His Ala Ser Ile Pro Phe Lys Leu  
 530 535 , 540

Lys Arg Gln Glu Ser Arg Thr Glu Ser Thr Arg Ala Glu Gly Val Lys  
545 550 555 560

Ser Ser Gly Thr Asn Ser Lys Asp Glu Leu  
565 570

<210> 11  
<211> 891  
<212> DNA  
<213> Zea mays

<210> 12  
<211> 220  
<212> PRT  
<213> Zea mays

<400> 12  
Ala Arg Val Glu Met Asp Asn Glu Asp Val Gly Lys Pro Val Ser Glu  
1 5 10 15

Tyr Phe Gly Ile Ser Gly Asn Ala Pro Lys Val Leu Gly Tyr Thr Gly  
                  20                 25                 30

Asn Asp Asp Gly Lys Lys Phe Val Leu Asp Gly Glu Val Thr Thr Asp  
 35 40 45

Lys Ile Lys Ala Phe Gly Glu Asp Phe Val Glu Asp Lys Leu Lys Pro  
50 55 60

Phe Tyr Lys Ser Asp Pro Val Pro Glu Ser Asn Asp Gly Asp Val Lys  
65 70 75 80

Ile Val Val Gly Asn Asn Phe Asp Glu Ile Val Leu Asp Glu Ser Lys  
85 90 95

Asp Val Leu Leu Glu Ile Tyr Ala Pro Trp Cys Gly His Cys Gln Ser  
100 105 110

Leu Glu Pro Ile Tyr Asn Lys Leu Ala Lys His Leu Arg Asn Ile Asp  
115 120 125

Ser Leu Val Ile Ala Lys Met Asp Gly Thr Thr Asn Glu His Pro Arg  
130 135 140

Ala Lys Pro Asp Gly Phe Pro Thr Leu Leu Phe Phe Pro Ala Gly Asn  
145 150 155 160

Lys Ser Phe Asp Pro Ile Thr Val Asp Thr Asp Arg Thr Val Val Ala  
165 170 175

Phe Tyr Lys Phe Leu Lys Lys His Ala Ser Ile Pro Phe Lys Leu Gln  
180 185 190

Lys Pro Thr Ser Thr Ser Glu Ser Asp Ser Lys Gly Ser Ser Asp Ala  
195 200 205

Lys Glu Ser Gln Ser Ser Asp Val Lys Asp Glu Leu  
210 215 220

<210> 13

<211> 1126

<212> DNA

<213> Glycine max

<400> 13

gcacgagcaa gttccattt gttacaatgc tgactgaaat gaattctatc agagtctact 60  
ccagcccat caagcttcaag gttttactct ttgcaaaatc tgatgacttc aagaatcttc 120  
ttgaaatctc tcaagatgtt gcaaaaacat tcaagtcaaa gataatgttt atataatgtgg 180  
atattaatgtg tgaaacccctt gcaaggccctt tcttaatcatc gtttggcttt qaagaatctac 240  
aaaatactgtt ggtccgcgcata ttgtatataatc caatgagctc aaaaatattttt ttggagacaa 300  
aaccacacaa aagcaatattt gaagaggttt gcaataacact tggcaagggg tctttgtcact 360  
cttacttcaat gtcacagcata attccagata atacaagata aagtgtccat gttattgtcact 420  
ggaaaaacatt tgatgtgaa atcttgagca ggcggaaaggaa tggctcttgg gaggatattt 480  
cgcccttggcgtcataactgtt gaggccactt gcaagcaactt agagaatgtt gcaaaagcact 540  
acaacggatc aagtaatctta atatttgcataa ggatagatgtc ttcaagcaaat gaacatccaa 600  
aactgcaagt gaatgactac cccacgcttc tactttacag acgacagcat aaggcaaatc 660  
cgatcaaaat ttccacaaatc ttcaatgttgc aagaggttgg tgcattccatt aacaatataatc 720  
taaaaatccaa gaatcaatgc gtcacaaatgc agtttgcatacatatcaaaa atgtttggaa 780  
gaaaaacactt taacccatgaa gaaaatggaaa cattatggaa agaaacaaaat attatgttgt 840  
cttgcgttaatc catttttcaatc ctttttccatc gocattttat ggtgggtccaa 900  
atatggatca gtcattattt atttggatca gcttactgtc aatattgcataa agtgcattca 960  
attataatcat gtaatggatca acgacatcatac ttgtatgcataa caaacatgtt accgtatcact 1020  
actttccatc tgcattctatc agaaacccgtc ttgtatgcataa cttaaaatgtt atgcattgac 1080  
acatataatcaatc ctcacatgtt tataattcga aaaaaaaaaaaaaaaa 1126

<210> 14  
<211> 251  
<212> PRT  
<213> Glycine max

<400> 14  
Thr Ser Lys Phe Pro Leu Val Thr Lys Leu Thr Glu Met Asn Ser Ile  
1 5 10 15  
Arg Val Tyr Ser Ser Pro Ile Lys Leu Gln Val Leu Val Phe Ala Asn  
20 25 30  
Ile Asp Asp Phe Lys Asn Leu Leu Glu Thr Leu Gln Asp Val Ala Lys  
35 40 45  
Thr Phe Lys Ser Lys Ile Met Phe Ile Tyr Val Asp Ile Asn Asp Glu  
50 55 60  
Asn Leu Ala Lys Pro Phe Leu Thr Leu Phe Gly Leu Glu Glu Ser Lys  
65 70 75 80  
Asn Thr Val Val Ala Ala Phe Asp Asn Ala Met Ser Ser Lys Tyr Leu  
85 90 95  
Leu Glu Thr Lys Pro Thr Gln Ser Asn Ile Glu Glu Phe Cys Asn Asn  
100 105 110  
Leu Val Gln Gly Ser Leu Ser Pro Tyr Phe Lys Ser Gln Pro Ile Pro  
115 120 125  
Asp Asn Thr Glu Ser Ser Val His Val Ile Val Gly Lys Thr Phe Asp  
130 135 140  
Asp Glu Ile Leu Ser Ser Glu Lys Asp Val Leu Leu Glu Val Phe Thr  
145 150 155 160  
Pro Trp Cys Ile Asn Cys Glu Ala Thr Ser Lys Gln Val Glu Lys Leu  
165 170 175  
Ala Lys His Tyr Lys Gly Ser Ser Asn Leu Ile Phe Ala Arg Ile Asp  
180 185 190  
Ala Ser Ala Asn Glu His Pro Lys Leu Gln Val Asn Asp Tyr Pro Thr  
195 200 205  
Leu Leu Leu Tyr Arg Ala Asp Asp Lys Ala Asn Pro Ile Lys Leu Ser  
210 215 220  
Thr Lys Ser Ser Leu Lys Glu Leu Ala Ala Ser Ile Asn Lys Tyr Val  
225 230 235 240  
Lys Val Lys Asn Gln Val Val Lys Asp Glu Leu  
245 250

<210> 15  
<211> 1943  
<212> DNA  
<213> Glycine max

<400> 15		60				
gttcttcata	ctctcacaat	gcaaatcctc	gttgtgtct	cttcgcac	cctccctc	120
tttccctccc	tttttcctac	cctctgcgac	gacccacccg	acgacgagg	cctcggttc	180
ctcgacgacg	cctccgcgcg	ggccggagac	ggccatcc	acgacgat	cgccaaat	300
ggcgaactcg	aggaggaccc	ggaggcgac	aacgacccg	agggtgacg	gaaaggacgt	360
gtcatttga	aggagaagaa	cttaccgc	acgcgtcaaga	gcaaccgcgt	cgccatggtc	420
gaggtttcacg	cgccctgtgt	cgccacgtc	caggccgtcg	cgccggagta	cgccggcc	480
gcccggaaac	tcggggcga	agactaatt	ttggcaaaa	ttgtatcc	ccggaggata	540
gaattggcgc	agcagtaga	ttgttcagggt	ttccccact	ttcaacttct	cggtatggc	600
attccaaacg	cttataatgg	ccaaaggacc	aaagatgtca	ttgtgcgt	gataggaaag	660
aaatgcgcac	ctggcatata	caacttgact	gtggcgagg	atgtcaacg	catcttgcg	720
aacgaaacta	aagtgtttt	gggtttcc	acacttttag	ttgtctcgta	gagtggagg	780
tttgcgtgt	cttcaagact	tgaggatgt	gtcaatttt	atcaacttg	gtatcttg	840
gtggcaaaagc	ttttccatat	tgaccaggat	gtaagcgcc	cagctttgt	cctcgtcaag	900
aaaggaggagg	aaaaaaatca	ccactttgt	ggcaaaat	agaatcgga	atagcgac	960
ttttgtctct	ccaaacaact	ttctttgt	aaatttttt	caagaaag	tgccccat	1020
gtcttcgaaa	atccaatcaa	gaaaacgtg	ttgtctgtt	caacttcaa	tgattcagag	1080
aagtgtatcc	ctgcattaa	agaagtcga	aaattttca	ggggaaatgt	gatctttgtt	1140
tatgtgtatc	tgatatacga	agatgttgg	acgcgtgtt	oagaacttct	ttgtatcaagt	1200
gggatgtcgc	caaaaactgt	ttggtactact	gggaatgtat	ttggaaaaaa	attttgtctt	1260
gatggagagg	tgactgtca	ggaaatattag	tttttttttt	tttttttttt	tttttttttt	1320
ctaaaaaccc	tttacaatgc	ccatccagg	tttttttttt	tttttttttt	tttttttttt	1380
tgatgttgg	ataatttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1440
attatgtgtc	ctctgtgtgg	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1500
aaacatcttc	gtataatgg	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1560
cateccagg	ctaaatgtca	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1620
atgtttgtac	tttattatgt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1680
aaagaaacatc	catcaatccc	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1740
ggggatctcg	atggccaaag	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1800
aaagtatata	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1860
gagaaaaatac	caagctgttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1920
agagacaaa	ttggggcgcac	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1980
tttagaaattt	ttgggttgaga	tttttttttt	tttttttttt	tttttttttt	tttttttttt	2040
aaaaaaaaaa	ttggactatct	tttttttttt	tttttttttt	tttttttttt	tttttttttt	2100

<210> 16  
<211> 551  
<212> PRT  
<213> Glycine max

<400> 16  
Met Arg Ile Leu Val Val Leu Ser Leu Ala Thr Leu Leu Leu Phe Ser  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Ser Leu Phe Leu Thr Leu Cys Asp Asp Leu Thr Asp Asp Glu Asp Leu  
 20 25 30  
 Gly Phe Leu Asp Glu Pro Ser Ala Ala Pro Glu His Gly His Tyr His

Asp Asp Asp Ala Asn Phe Gly Asp Phe Glu Glu Asp Pro Glu Ala Tyr

Lys Gln Pro Glu Val Asp Glu Lys Asp Val Val Ile Leu Lys Glu Lys  
65 70 75 80

Asn	Phe	Thr	Asp	Thr	Val	Lys	Ser	Asn	Arg	Phe	Val	Met	Val	Glu	Phe
85								90						95	

Tyr Ala Pro Trp Cys Gly His Cys Gln Ala Leu Ala Pro Glu Tyr Ala  
 100 105 110  
 Ala Ala Ala Thr Glu Leu Lys Gly Glu Asp Val Ile Leu Ala Lys Val  
 115 120 125  
 Asp Ala Thr Glu Glu Asn Glu Leu Ala Gln Gln Tyr Asp Val Gln Gly  
 130 135 140  
 Phe Pro Thr Val His Phe Phe Val Asp Gly Ile His Lys Pro Tyr Asn  
 145 150 155 160  
 Gly Gln Arg Thr Lys Asp Ala Ile Val Thr Trp Ile Gly Lys Lys Ile  
 165 170 175  
 Gly Pro Gly Ile Tyr Asn Leu Thr Thr Val Glu Asp Ala Gln Arg Ile  
 180 185 190  
 Leu Thr Asn Glu Thr Lys Val Val Leu Gly Phe Leu Asn Ser Leu Val  
 195 200 205  
 Gly Pro Glu Ser Glu Glu Leu Ala Ala Ala Ser Arg Leu Glu Asp Asp  
 210 215 220  
 Val Asn Phe Tyr Gln Thr Val Asp Pro Asp Val Ala Lys Leu Phe His  
 225 230 235 240  
 Ile Asp Pro Asp Val Lys Arg Pro Ala Leu Ile Leu Val Lys Lys Glu  
 245 250 255  
 Glu Glu Lys Leu Asn His Phe Asp Gly Lys Phe Glu Lys Ser Glu Ile  
 260 265 270  
 Ala Asp Phe Val Phe Ser Asn Lys Leu Pro Leu Val Thr Ile Phe Thr  
 275 280 285  
 Arg Glu Ser Ala Pro Ser Val Phe Glu Asn Pro Ile Lys Lys Gln Leu  
 290 295 300  
 Leu Leu Phe Ala Thr Ser Asn Asp Ser Glu Lys Leu Ile Pro Ala Phe  
 305 310 315 320  
 Lys Glu Ala Ala Lys Ser Phe Lys Gly Lys Leu Ile Phe Val Tyr Val  
 325 330 335  
 Glu Met Asp Asn Glu Asp Val Gly Lys Pro Val Ser Glu Tyr Phe Gly  
 340 345 350  
 Ile Ser Gly Asn Ala Pro Lys Val Leu Gly Tyr Thr Gly Asn Asp Asp  
 355 360 365  
 Gly Lys Lys Phe Val Leu Asp Gly Glu Val Thr Ala Asp Lys Ile Lys  
 370 375 380  
 Ala Phe Gly Asp Asp Phe Leu Glu Asp Lys Leu Lys Pro Phe Tyr Lys  
 385 390 395 400  
 Ser Asp Pro Val Pro Glu Ser Asn Asp Gly Asp Val Lys Ile Val Val  
 405 410 415

Gly Asn Asn Phe Asp Glu Ile Val Leu Asp Glu Ser Lys Asp Val Leu  
 420 425 430

Leu Glu Ile Tyr Ala Pro Trp Cys Gly His Cys Gln Ala Leu Glu Pro  
435 440 445

Ile Tyr Asp Lys Leu Ala Lys His Leu Arg Asn Ile Glu Ser Leu Val  
450 455 460

Ile Ala Lys Met Asp Gly Thr Thr Asn Glu His Pro Arg Ala Lys Pro  
465 470 475 480

Asp Gly Phe Pro Thr Leu Leu Phe Phe Pro Ala Gly Asn Lys Ser Phe  
485 490 495

Asp Pro Ile Thr Val Asp Thr Asp Arg Thr Val Val Ala Phe Tyr Lys  
500 505 510

Phe Leu Lys Lys His Ala Ser Ile Pro Phe Lys Leu Gln Lys Pro Thr  
515 520 525

Ser Thr Ser Asp Ala Lys Gly Ser Ser Asp Ala Lys Glu Ser Gln Ser  
 530 535 540

Ser Asp Val Lys Asp Glu Leu  
545 550

<210> 17

<211> 1565

<212> DNA

<213> *Triticum aestivum*

<400> 17

gcacgagacc ...

cagctcatgc  
ggatccggatc

gccttcgcga  
ggatccggatc

<210> 18  
<211> 451  
<212> PRT  
<213> Triticum aestivum

<400> 18  
Ala Arg Asp His Ala Glu Leu Leu Leu Leu Gly Tyr Ala Pro Trp Cys  
1 5 10 15  
Glu Arg Ser Ala Gln Leu Met Pro Arg Phe Ala Glu Ala Ala Ala Ala  
20 25 30  
Leu Arg Ala Met Gly Ser Ala Val Ala Phe Ala Lys Leu Asp Gly Glu  
35 40 45  
Arg Tyr Pro Lys Ala Ala Ala Val Gly Val Lys Gly Phe Pro Thr  
50 55 60  
Val Leu Leu Phe Val Asn Gly Thr Glu His Ala Tyr His Gly Leu His  
65 70 75 80  
Thr Lys Asp Ala Ile Val Thr Trp Val Arg Lys Lys Thr Gly Glu Pro  
85 90 95  
Ile Ile Arg Leu Gln Ser Lys Asp Ser Ala Glu Glu Phe Leu Lys Lys  
100 105 110  
Asp Met Thr Phe Val Ile Gly Leu Phe Lys Asn Phe Glu Gly Ala Asp  
115 120 125  
His Glu Glu Phe Val Lys Ala Ala Thr Thr Asp Asn Glu Val Gln Phe  
130 135 140  
Val Glu Thr Ser Asp Thr Arg Val Ala Lys Val Leu Phe Pro Gly Ile  
145 150 155 160  
Thr Ser Glu Glu Phe Val Gly Leu Val Lys Ser Glu Pro Glu Lys  
165 170 175  
Phe Glu Lys Phe Asp Gly Lys Phe Glu Glu Thr Glu Ile Leu Arg Phe  
180 185 190  
Val Glu Leu Asn Lys Phe Pro Leu Ile Thr Val Phe Thr Glu Leu Asn  
195 200 205  
Ser Gly Lys Val Tyr Ser Ser Pro Ile Lys Leu Gln Val Phe Thr Phe  
210 215 220  
Ala Glu Ala Tyr Asp Phe Glu Asp Leu Glu Ser Met Val Glu Glu Ile  
225 230 235 240  
Ala Arg Ala Phe Lys Thr Lys Ile Met Phe Ile Tyr Val Asp Thr Ala  
245 250 255  
Glu Glu Asn Leu Ala Lys Pro Phe Leu Thr Leu Tyr Gly Leu Glu Ser  
260 265 270  
Glu Lys Lys Pro Thr Val Thr Ala Phe Asp Thr Ser Asn Gly Ala Lys  
275 280 285



<210> 20  
<211> 294  
<212> PRT  
<213> Triticum aestivum

<400> 20  
Thr Arg Phe Arg Ala Ser Ala Ile Ala Lys Phe Val Ser Ala Asn Lys  
1 5 10 15  
Ile Pro Leu Ile Thr Thr Leu Thr Gln Glu Thr Ala Pro Ala Ile Phe  
20 25 30  
Asp Asn Pro Ile Lys Lys Gln Ile Leu Leu Phe Ala Val Ala Lys Glu  
35 40 45  
Ser Ser Lys Phe Leu Pro Ile Ile Lys Glu Thr Ala Lys Ser Phe Lys  
50 55 60  
Gly Lys Leu Leu Phe Val Phe Val Glu Arg Asp Asn Glu Glu Val Gly  
65 70 75 80  
Glu Pro Val Ala Asn Tyr Phe Gly Ile Thr Gly Gln Glu Thr Thr Val  
85 90 95  
Leu Ala Tyr Thr Gly Asn Glu Asp Ala Lys Lys Phe Phe Thr Thr Gly  
100 105 110  
Glu Ile Ser Leu Asp Thr Ile Lys Glu Phe Ala Gln Asp Phe Met Glu  
115 120 125  
Asp Lys Leu Thr Pro Ser Tyr Lys Ser Asp Pro Val Pro Glu Ser Asn  
130 135 140  
Asp Glu Asp Val Lys Val Val Val Gly Lys Ser Leu Asp Gln Ile Val  
145 150 155 160  
Leu Asp Glu Ser Lys Asp Val Leu Leu Glu Ile Tyr Ala Pro Trp Cys  
165 170 175  
Gly His Cys Gln Ser Leu Glu Pro Ile Tyr Asn Lys Leu Ala Lys Tyr  
180 185 190  
Leu Arg Gly Ile Asp Ser Leu Val Ile Ala Lys Met Asp Gly Thr Asn  
195 200 205  
Asn Glu His Pro Arg Ala Lys Pro Asp Gly Phe Pro Thr Ile Leu Phe  
210 215 220  
Tyr Pro Ala Gly Lys Lys Ser Phe Glu Pro Ile Thr Phe Glu Gly Gly  
225 230 235 240  
Arg Thr Val Val Glu Met Tyr Lys Phe Leu Lys Lys His Ala Ala Ile  
245 250 255  
Pro Phe Lys Leu Lys Arg Pro Asp Ser Ser Ala Ala Arg Thr Asp Ser  
260 265 270  
Ala Glu Gly Pro Gly Ser Thr Thr Asp Ser Glu Lys Ser Ser Gly Ser  
275 280 285

Asn Pro Lys Asp Glu Leu  
290